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A B S T R A C T
Background
This is a second update of a Cochrane Review originally published in Issue 2, 2009. Transcutaneous Electrical Nerve Stimulation
(TENS) is a non-pharmacological agent, based on delivering low voltage electrical currents to the skin. TENS is used by people to treat
a variety of pain conditions.
Objectives
To assess the analgesic effectiveness of TENS, as a sole treatment, for acute pain in adults.
Search methods
We searched the following databases up to 3 December 2014: the Cochrane Central Register of Controlled Trials (CENTRAL), in the
Cochrane Library; MEDLINE; EMBASE; CINAHL; and AMED. We also checked the reference lists of included trials.
Selection criteria
We included randomised controlled trials (RCTs) of adults with acute pain (< 12 weeks) if they examined TENS given as a sole
treatment and assessed pain with subjective pain scales. Trials were eligible if they compared TENS to placebo TENS, no treatment
controls, pharmacological interventions or non-pharmacological interventions. We excluded trials on experimental pain, case reports,
clinical observations, letters, abstracts or reviews. Also we excluded trials investigating the effect of TENS on pain during childbirth
(labour), primary dysmenorrhoea or dental procedures. Studies where TENS was given with another treatment as part of the formal
trial design were excluded. We did not restrict any articles based on language of publication.
Data collection and analysis
Two review authors independently assessed study eligibility and carried out study selection, data extraction, ’Risk of bias’ assessment
and analyses of data. We extracted data on the following: types of participants and pain condition, trial design and methods, treatment
parameters, adverse effects, and outcome measures. We contacted trial authors for additional information if necessary.
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Main results
We included 12 trials in the original review (2009) and included no further trials in the first update (2011). An additional seven new
trials met the inclusion criteria in this second update. In total, we included 19 RCTs involving 1346 participants at entry, with 11
trials awaiting classification either because the full text was unavailable or information in the full text failed to clarify eligibility. We
excluded most trials because TENS was given in combination with another treatment as part of the formal study design or TENS
was not delivered using appropriate TENS technique. The types of acute pain included in this Cochrane Review were procedural
pain, e.g. cervical laser treatment, venepuncture, screening flexible sigmoidoscopy and non-procedural pain, e.g. postpartum uterine
contractions and rib fractures. We pooled data for pain intensity for six trials (seven comparisons) comparing TENS with placebo but
the I2 statistic suggested substantial heterogeneity. Mean difference (MD) with 95% confidence intervals (CIs) on a visual analogue
scale (VAS, 100 mm) was -24.62 mm (95% CI -31.79 to -17.46) in favour of TENS. Data for the proportion of participants achieving
≥ 50% reduction in pain was pooled for four trials (seven comparisons) and relative risk was 3.91 (95% CI 2.42 to 6.32) in favour of
TENS over placebo. We pooled data for pain intensity from five trials (seven comparisons) but the I2 statistic suggested considerable
heterogeneity. MD was -19.05 mm (95% CI -27.30 to -10.79) in favour of TENS using a random-effects model. It was not possible
to pool other data. There was a high risk of bias associated with inadequate sample sizes in treatment arms and unsuccessful blinding
of treatment interventions. Seven trials reported minor adverse effects, such as mild erythema and itching underneath the electrodes
and participants disliking TENS sensation.
Authors’ conclusions
This Cochrane Review update includes seven new trials, in addition to the 12 trials reviewed in the first update in 2011. The
analysis provides tentative evidence that TENS reduces pain intensity over and above that seen with placebo (no current) TENS when
administered as a stand-alone treatment for acute pain in adults. The high risk of bias associated with inadequate sample sizes in
treatment arms and unsuccessful blinding of treatment interventions makes definitive conclusions impossible. There was incomplete
reporting of treatment in many reports making replication of trials impossible.
P L A I N L A N G U A G E S U M M A R Y
Transcutaneous Electrical Nerve Stimulation (TENS) to treat acute pain in adults
Background
Acute pain is pain of recent onset and limited duration. Acute pain is associated with surgery, physical trauma (e.g. broken bones, burns
and cuts) and medical procedures (e.g. venepuncture and sigmoidoscopy). Transcutaneous Electrical Nerve Stimulation (TENS) is a
treatment to relieve pain by administering mild electrical currents to the body using electrode pads attached to the surface of the skin.
Review question
Does TENS relieve acute pain in adults?
Study characteristics
We included 19 clinical trials published up to 3 December 2014, which examined 1346 people. The trials administered TENS to
produce a strong non painful ’tingling’ sensation at the site of acute pain. The trials assessed TENS for cervical laser treatment,
venepuncture, sigmoidoscopy, rib fractures and uterine contractions after childbirth. We did not include trials that assessed TENS for
pain associated with childbirth, dental procedures and menstruation because they have been the subject of other Cochrane Reviews.
Eleven trials are awaiting classification.
Key results
TENS was better than placebo TENS (delivering no electrical current) at reducing the intensity of acute pain but the reduction in pain
was not consistent across all trials. This finding was based on an analysis of only six of the 19 trials. There was an insufficient number
patients to make a firm conclusion.
A small number of patients experienced itching and redness beneath the TENS pads or disliked the sensation produced by TENS.
Overall we concluded that TENS may reduce the intensity of acute pain in some patients but the quality of evidence was weak. TENS
is inexpensive, safe and can be self-administered. We recommended that TENS should be considered as a treatment option given on
its own or in combination with other treatments.
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Quality of the evidence
The quality of the evidence was moderate to low because sample sizes were small and some patients were aware that they were receiving
TENS or placebo.
B A C K G R O U N D
This Cochrane Review is a second update of Walsh 2009, and
replaces the 2011 update.
Description of the condition
The International Association for the Study of Pain defines pain as
“an unpleasant sensory and emotional experience associated with
actual or potential tissue damage, or described in terms of such
damage” (Merskey 1994). Acute pain is defined as pain “of recent
onset and probable limited duration which usually has an identifi-
able temporal and causal relationship to the injury or disease”. In
clinical practice acute pain is categorised as pain of less than three
months duration (Strong 2002). Current approaches to acute pain
management include pharmacological agents (drugs) and a num-
ber of non-pharmacological agents, one of which is Transcuta-
neous Electrical Nerve Stimulation (TENS) (Schug 2014).
Description of the intervention
TENS is the delivery of pulsed electrical currents across the intact
surface of the skin to stimulate peripheral nerves principally for
pain relief (Johnson 2014). In clinical practice TENS is adminis-
tered using a portable, battery-powered device that generates elec-
trical currents that are delivered to the body via electrodes attached
to the intact surface of the skin. TENS is inexpensive and can be
self-administered. The safety profile of TENS compares positively
compared with medication. Safety guidelines published by profes-
sional bodies guide judgements about whether it is appropriate to
use TENS (Houghton 2010). Contradictions include TENS for
patients who also have electronic implants, such as cardiac pace-
makers and implantable cardioverter defibrillators. Precautions in-
clude pregnancy, epilepsy, active malignancy, deep-vein thrombo-
sis, and frail or damaged skin.
How the intervention might work
Natural forms of electricity (e.g. electrogenic fish) have been used
as a method of pain relief since the Egyptian era (Johnson 2014).
A theoretical foundation for electroanalgesia (pain relief by elec-
trical methods) was established in 1965 through the publication
of Melzack andWall’s gate control theory of pain (Melzack 1965).
This theory proposed that ametaphorical gate consisting of excita-
tory and inhibitory synapses existed in the dorsal horn of the spinal
cord. The gate could regulate the amount of nociceptive traffic
(painful stimuli) being transmitted onwards to the brain. This gate
could be opened by noxious stimuli that excited high threshold
small diameter peripheral afferents and could be closed by non-
noxious stimuli (e.g. touch, pressure and electrical currents) that
excited low threshold large diameter peripheral afferents.
Technological advances have produced a variety of TENS devices
with a wide range of stimulation parameters for clinicians and pa-
tients to choose from (e.g. pulse frequency, pulse amplitude, pulse
duration and electrode placement site). TENS interventions tend
to be described according to technical characteristics as either high
frequency, low intensity (conventional TENS) or low frequency,
high intensity (acupuncture-like TENS, AL-TENS). This techni-
cal approach fails to specify the physiological intention of deliver-
ingTENS. In this regard, the physiological intentionwhen admin-
istering conventional TENS is to activate selectively non-noxious
low threshold afferent nerve fibres in the skin (Aβ-fibres) which
are claimed to inhibit transmission of nociceptive information at
the level of the spinal cord (i.e. segmentalmodulation) (DeSantana
2008). In practice, Aβ nerve fibre activity is recognised by the user
reporting strong electrical paraesthesia (pins and needles) beneath
the electrodes. The physiological intention of AL-TENS is to gen-
erate a muscle twitch which is believed to increase activity in small
diameter afferent nerve fibres in muscles (Aδ) leading to activation
of descending pain inhibitory pathways. In practice, AL-TENS is
achieved by administering low frequency and high intensity, but
non-painful, currents over muscles (Francis 2011). Interestingly,
experimental evidence to establish the roles of different afferent
fibres in TENS outcome is inconclusive (Garrison 1994; Levin
1993; Radhakrishnan 2005). Research suggests that different fre-
quencies of TENSmay act through different neurotransmitter sys-
tems. Sluka and colleagues conducted a series of animal studies
that have shown that low frequency TENS-induced antihyperal-
gesia (decreased sensitivity to pain) is mediated by activation of
serotonin and mu opioid receptors, while high frequency TENS
activates delta opioid receptors (Kalra 2001; Radhakrishnan 2003;
Sluka 1999). In 2008, a systematic review evaluating frequency
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dependent effects on experimentally induced pain in humans was
inconclusive due to an insufficient number of high quality trials
(Chen 2008). In recent years frequency-dependent effects have
been confirmed in human subjects by high quality research studies
(Chen 2010a; Chen 2010b; Chen 2011; Claydon 2011; Leonard
2010; Léonard 2011; Liebano 2011).
Why it is important to do this review
TENS is used extensively by people with acute and chronic pain
(DeSantana 2008; Johnson 2011). Meta-analyses on the effective-
ness of TENS for chronic musculoskeletal pain (Johnson 2007)
and for osteoarthritis of the knee (Bjordal 2007) demonstrated
a significant effect on pain over placebo. Cochrane Reviews on
TENS for specific chronic pain conditions have been hindered by
methodological weaknesses in randomised controlled trials (RCTs)
(Bennett 2011; Johnson 2010; Johnson 2014; Sluka 2013). An all-
encompassing Cochrane Review on TENS for a variety of chronic
pain conditions (i.e. pain > three months’ duration) reported in-
conclusive results (Nnoaham 2008).However, this review has now
been withdrawn and is being replaced by new reviews on TENS
for neuropathic pain in adults, led by Gibson (protocol in press)
and TENS for fibromyalgia, led by Claydon et al (protocol in
press). There is also a title registered for an overview of Cochrane
Reviews of TENS for chronic pain (protocol in press).
Cochrane Reviews on TENS for specific types of acute pain have
been inconclusive for labour pain (Dowswell 2009) and dysmen-
orrhoea (Proctor 2002). An early systematic review of TENS for
post-operative pain found TENS to be no better than controls for
postoperative pain (Carroll 1996) although pain measures were
taken when patients were allowed free access to analgesic medi-
cation. This compromises pain scores because patients in placebo
and TENS groups titrate analgesic medication to achieve effective
pain relief, and therefore exhibit similar pain scores. Review au-
thors also included trials that underdosed TENS or used an in-
appropriate TENS technique, or both. A meta-analysis with sub-
group analysis demonstrated a significantly better outcome for
TENS when applied using adequate (optimal) stimulation tech-
niques when compared to non-adequate stimulation techniques
(Bjordal 2003); optimal TENS techniques were defined as an in-
tensity that was strong enough to generate a strong paraesthesia
and electrodes applied at the site of the operative scar. Recent ev-
idence from systematic reviews suggests that TENS is superior to
placebo TENS when used in combination with analgesic medi-
cation for thoracotomy and post-sternotomy pain (Freynet 2010;
Sbruzzi 2012). To date, there has been no all-encompassing sys-
tematic reviewonTENS for acute pain. A systematic review,which
takes account of adequate TENS techniques, is necessary to assist
clinicians and researchers to make informed decisions on the effec-
tiveness of this modality for acute pain. TENS can be given either
as a sole treatment, i.e. stand alone treatment, or combined with
other interventions. This Cochrane Review will focus on TENS
given as a sole treatment only to see if it has sufficient efficacy in
its own right.
O B J E C T I V E S
Primary objective
To assess the analgesic effectiveness of TENS, as a sole treatment,
for acute pain in adults.
Secondary objectives
To assess whether:
1. TENS effectiveness is influenced by the type of TENS (i.e.
conventional TENS versus AL-TENS);
2. TENS effectiveness is influenced by the time of recording
the outcome measure, i.e. if outcome is influenced by
measurements taken when TENS is switched on (during TENS
measurement) compared to when TENS has been turned off
after the treatment (post-TENS measurement);
3. TENS effectiveness is influenced by duration of TENS
treatment;
4. TENS effectiveness differs for different acute pain
conditions; and,
5. TENS is safe for the treatment of acute pain.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all prospective RCTs. Both cross-over and parallel
trial designs were acceptable. We excluded data from the follow-
ing: trials that were non-randomised; studies of experimental pain;
case reports; clinical observations; and letters, abstracts and re-
views (unless they provided additional information frompublished
RCTs that met the criteria).
Types of participants
Study participants were required to be adults (i.e. 16 years and
over) with a diagnosis of acute pain (less than 12 weeks) by any
cause including injury or surgical intervention. Acute pain con-
ditions included, but were not limited to, the following: angina;
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back pain; fractures; headache; musculoskeletal pain and proce-
dural pain. We included postpartum pain trials if the pain inves-
tigated was due to episiotomy or Caesarean section irrespective
of the presence of uterine cramps. We excluded trials including
patients with pain due to uterine contractions (i.e. labour) alone
and trials including patients with acute pain due to primary dys-
menorrhoea as these conditions have been covered by previous
Cochrane Reviews (Dowswell 2009; Proctor 2002). In addition,
we excluded trials on electrical stimulation for dental procedures
as this is a subject for a separate review.
Types of interventions
We only included trials which evaluated surface electrical nerve
stimulation for the treatment of acute pain (i.e. transcutaneous
as opposed to percutaneous electrical stimulation). We defined
appropriate delivery of TENS as follows:
1. A ’standard TENS device’ was used which delivered
biphasic or monophasic (type of waveform) pulsed electrical
currents in the mA range. TENS had to be delivered using at
least two surface electrodes. We excluded TENS delivered using
single probes (i.e. TENS pens). Neuromuscular electrical
stimulation (NMES) devices and Interferential Current devices
were excluded;
2. TENS was administered to produce a strong electrical
paraesthesia that was felt by the patient. We included AL-TENS
delivered at strong intensities to generate muscle twitches. We
excluded trials if the active TENS intervention was delivered at
intensities reported to be ’barely perceptible’, ’faint’ or ’mild’;
3. TENS was administered on an area of the body which was
sensate (where pain is being felt) at either (a) the site of pain or
(b) over nerve bundles proximal (or near) to the site of pain. We
only included TENS delivered at acupuncture stimulation points
if the point was lying over nerve bundles proximal (or near) to
the site of pain. We considered any parameters of treatment
meeting these criteria as were any duration or frequency of
treatment and either self-applied or therapist-applied treatments.
The interventions to be compared included the following:
• TENS versus placebo TENS (i.e. use of a sham TENS
device). We defined a sham TENS device as a device similar to
the one used in the active group but the output was modified in
some way so that either no electrical current or a barely
perceptible electrical current is delivered through the electrodes;
• TENS versus no treatment controls;
• TENS versus a pharmacological intervention;
• TENS versus a non-pharmacological intervention.
We excluded trials if TENS was given in combination with any
other treatment as part of the formal trial design, e.g. analgesic
medication, exercise.
Types of outcome measures
Primary outcomes
• Standard subjective scales for pain intensity, pain relief or
both (e.g. visual analogue scales (VAS), numerical rating scales
(NRS); verbal rating scales (VRS) McGill Pain Questionnaire
(MPQ)).
Secondary outcomes
• Other measures of pain.
We recorded adverse events associated with the intervention. Also,
we sought information on the level of compliance with the inter-
vention, the magnitude and duration of effect.
Search methods for identification of studies
Electronic searches
Wedevelopeddetailed search strategies for each electronic database
searched. We based these on the search strategy developed for
MEDLINE but revised each strategy appropriately for each
database. The search strategy combined the subject specific search
with phase one and two of the Cochrane Sensitive Search Strategy
for RCTs (as published in chapter sections 6.4.11.1, 6.3.2.1 and
6.3.3.2 in the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011). The subject specific search used a combi-
nation ofMeSH (upper case) and free text (lower case) terms based
on the MEDLINE search strategy via OVID which can be seen in
Appendix 1. We attempted to identify all relevant trials irrespec-
tive of language. We assessed non-English papers and translated
articles when necessary.
We performed the literature search for Walsh 2009 up to 8 Au-
gust 2008 and subsequent searches up to 7 January 2011 for
the 2011 review update. For this second search update we per-
formed searches up to 3 December 2014. We searched the follow-
ing databases:
• Cochrane Pain, Palliative and Supportive Care Group
(PaPaS) Specialized Register (4 August 2008; as data are captured
in CENTRAL, we did not include this database in the 2011 or
2013 update search) Appendix 2;
• Cochrane Central Register of Controlled Trials, CENTRAL
(the Cochrane Library, Issue 11 of 12, 2014) Appendix 3;
• MEDLINE (1950 to Nov week 3 2014) Appendix 1;
• EMBASE (1980 to 2 Dec 2014) Appendix 4;
• CINAHL (1982 to 6 Dec 2014) Appendix 5;
• AMED (1985 to 6 November 2014) Appendix 6;
• PEDro (www.pedro.org.au) accessed 7 January 2011. We
excluded this database from the 2013 update search Appendix 7;
• OTseeker (www.otseeker.com) accessed 7 January 2011. We
excluded this database from the 2013 update search Appendix 8;
and,
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• OpenSIGLE (http://opensigle.inist.fr) accessed 7 January
2011. We excluded this database from the 2013 update search
Appendix 9.
Searching other resources
We searched the reference lists of all included trials, key textbooks
and previous systematic reviews for additional trials.
Data collection and analysis
Selection of studies
From the title, abstract, and descriptors, pairs of review authors
independently reviewed the results of the literature searches to
identify potentially relevant trials for full review. We resolved any
disagreements by consensus. We did not blind the review authors
from authors’ names, institutions, and journal name or trial re-
sults at this stage or any stage of the review. After screening full
text articles, we included trials that met the inclusion criteria. We
sought additional information or clarification from the primary
trial author if incompletely reported.
Data extraction and management
Pairs of review authors independently extracted data using a cus-
tomised data extraction tool tested prior to use. We resolved any
disagreements by consensus or by consulting a third review author.
We contacted trial authors where there was incomplete reporting
of data. We extracted data on the following trial characteristics for
entry into RevMan 2014:
• Study participants: age, gender, condition, inclusion/
exclusion criteria, number of participants randomised, number
of, and reasons for, withdrawals or dropouts;
• Study: design and location, methods of sequence
generation and allocation concealment, blinding, intention-to-
treat (ITT) or per protocol analysis, outcome measures for pain,
and results of statistical analysis;
• Interventions used: where TENS was applied and by
whom, stimulation parameters (frequency, waveform, pulse
amplitude/intensity, pulse duration), electrode details, treatment
time and frequency, and adverse effects.
Assessment of risk of bias in included studies
We originally intended to assess the methodological quality of tri-
als using the scale devised by Jadad 1996 as detailed in the protocol.
However, with the launch of Review Manager (RevMan) in 2008,
we decided to use the Cochrane Collaboration’s ’Risk of bias’ as-
sessment tool as described in Chapter 8 of Higgins 2011. Two re-
view authors independently assessed the following: sequence gen-
eration, allocation concealment, blinding of participants and out-
come assessors, incomplete outcome data, and other sources of
bias (funding and size of trial). We resolved any disagreement by
consensus or by consulting a third review author.
Measures of treatment effect
Where available and appropriate, we presented quantitative data
for the outcomes listed in the inclusion criteria. For each trial,
we calculated relative risk and 95% confidence intervals (CI) for
dichotomous outcomes. For continuous outcomes reported using
the same scale, we determined mean differences (MD) and 95%
CIs.Where results for continuous outcomeswere presented on dif-
ferent scales, we calculated standardised mean differences (SMD)
and 95% CIs.We planned to calculate the number needed to treat
for an additional beneficial outcome (NNTB) for treatment effect.
Dealing with missing data
In cases of missing data due to withdrawals or dropouts, we only
used the data analysed in the trial for analysis in this Cochrane
Review.
Assessment of heterogeneity
We had intended that, where appropriate, we would pool results
of comparable groups of trials using the fixed-effect model and cal-
culate 95% CIs. We planned to test heterogeneity between com-
parable trials using a standard Chi² test considered statistically
significant at a P value < 0.1, after due consideration of the I2
statistic value.We interpreted the I2 statistic value according to the
following thresholds (Higgins 2011): 0% to 40%, might not be
important; 30% to 60%, may represent moderate heterogeneity;
50% to 90%, may represent substantial heterogeneity; and 75%
to 100%, considerable heterogeneity. We planned to investigate
any evidence of heterogeneity to determine if there were obvious
differences in the trials that were likely causes of the heterogeneity.
If the heterogeneity was regarded as likely to have serious effects
on the validity of the results, then we did not combine the data.
Where there was significant heterogeneity, we intended to view
the results of the random-effects model and present these when
appropriate.
Subgroup analysis and investigation of heterogeneity
Where the data allowed, we planned separate outcome analyses
to test the following null hypotheses that there is no difference in
analgesia:
1. Between AL-TENS (visible phasic muscle contractions) and
conventional TENS (no visible muscle contraction);
2. If the outcome measure is recorded during TENS
application;
3. Between different TENS treatment durations; and,
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4. Between different acute pain conditions.
R E S U L T S
Description of studies
Results of the search
For the 2011 update we identified 1775 reports in the literature
searches. For this update, 1421 records were identified through
database searching between 2011 and 2014. After removal of du-
plicates we screened the abstracts of 1065 reports (Figure 1). Of
these 1065 reports, 1038 were removed because they were not rel-
evant, did not meet the inclusion criteria, had administered TENS
in combination with another treatment as part of the formal trial
design (n=120) or had not administered TENS using appropri-
ate technique as defined in the Types of interventions section (n=
32). Hence this update included seven new trials (Amer-Cuenca
2011; de Sousa 2014; Ekblom 1987; Gregorini 2010; Keskin
2012; Kim 2012; Pitangui 2012), including two of the trials that
were awaiting classification in the 2011 update (Ekblom 1987;
Gregorini 2010). In total there were 19 trials included for review
(Characteristics of included studies) and all were published in En-
glish. Eleven trials were awaiting classification (Cambiaghi 2013;
de Paiva Tosato 2007; França 2012; Hsueh 1997; Liebano 2013;
Park 2014; Rajpurohit 2010; Salvador 2005; Salvino 2013; Silva
2012; Treacy 2011).
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Figure 1. Study flow diagram.
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Included studies
Participants
The 19 included trials had 1346 participants at entry (Amer-
Cuenca 2011; Cheing 2005; Coyne 1995; Crompton 1992; De
Angelis 2003; de Sousa 2014; Ekblom 1987; Gregorini 2010;
Hansson 1983; Hruby 2006; Keskin 2012; Kim 2012; Limoges
2004; Liu 1985; Olsén 2007; Oncel 2002; Ordog 1987; Pitangui
2012; Roche 1985). Two trials did not indicate the gender of
participants (Ordog 1987; Roche 1985), six trials included only
women (Crompton 1992; De Angelis 2003; de Sousa 2014;
Keskin 2012; Olsén 2007; Pitangui 2012) and the remaining 11
trials included women and men. There were 429 males and 759
females with an age range of 11 to 81 years in reports that provided
information about age. One report did not provide details about
the age of participants (Ordog 1987). Two trials included at least
one participant under 16 years of age in the sample population
(age range: Cheing 2005: 15 to 58 years; Oncel 2002: 11 to 81
years) but we included these trials because the mean age for both
sample populations was > 30 years. Seven trials investigated the
effect of TENS on procedural pain. Procedures included cervical
laser treatment (Crompton 1992), office hysteroscopy (De Angelis
2003), screening flexible sigmoidoscopy (Limoges 2004), flexible
cystoscopy (Hruby 2006), unsedated colonoscopy (Amer-Cuenca
2011) and venepuncture (Coyne 1995; Kim 2012). The remain-
ing trials investigated the effect of TENS on haemophilia pain
(Roche 1985), acute trauma such as sprains or fractures (Ordog
1987), postpartum uterine contractions (de Sousa 2014; Olsén
2007), acute lowback pain (LBP) during pregnancy (Keskin 2012)
acute orofacial pain (Ekblom 1987; Hansson 1983), post thora-
cotomy (Liu 1985), post-cardiac surgery (Gregorini 2010), post-
episiotomy (Pitangui 2012), rib fractures (Oncel 2002) and neu-
ropathic pain (Cheing 2005).
Setting
Studies were conducted in Europe (UK, Sweden, Turkey, Italy,
Spain), North America , Brazil and China, Hong Kong and South
Korea. Eighteen trials were conducted in a hospital or specialised
clinic with participants in one of these trials continuing to use
TENS at home after discharge (Oncel 2002). In one trial, partic-
ipants received TENS instruction in hospital but only used it at
home (Ordog 1987).
Design
All included RCTs used a parallel group design.
Sample sizes
The number of participants randomised to each treatment group
ranged from eight (Olsén 2007; Roche 1985) to 71 (De Angelis
2003). Ten trials had at least 20 participants in each of the treat-
ment groups (Amer-Cuenca 2011; Crompton 1992; De Angelis
2003; Hansson 1983; Hruby 2006; Kim 2012; Limoges 2004;
Oncel 2002; Ordog 1987; Pitangui 2012). Four trials performed
a prospective sample size calculation to determine the appropriate
number of participants required (Amer-Cuenca 2011; Crompton
1992; de Sousa 2014; Keskin 2012). Olsén 2007 reported that
they based their sample size on results from previous trials in the
area but did not provide a priori power analysis details; they per-
formed a post hoc power analysis on the data they collected and
claimed that the numbers they recruited (N = 13 and 8 in the two
groups) were adequate.
TENS device and application
Electrodes were placed at the painful site in all trials except Amer-
Cuenca 2011, where electrodes were placed over the sensory nerves
supplying the colon for unsedated colonoscopy, and Roche 1985,
where electrodes were placed over the painful area or close to the
area of bleeding for pain associated with haemophilia. Five trials
did not provide full details of the type, size, number of electrodes
used (Crompton 1992; De Angelis 2003; Hruby 2006; Liu 1985;
Ordog 1987). TENS was administered using two self-adhesive
electrodes or two rubber/silicone electrodes smeared with gel in
most trials. Crompton 1992 used four electrodes over the anterior
abdominal wall (painful area) and two over the sacrum for pain
experienced during cervical laser treatment. Limoges 2004 placed
two electrodes over the abdomen (painful area) and two electrodes
parallel to the spinal cord at L1-S3 level for screening flexible
sigmoidoscopy pain. Ordog 1987 used metal electrodes. Details
of the model or manufacturer of the TENS device used, or both,
was provided in all reports. Two trials used a device from the
same Swedishmanufacturer (Hansson 1983; Olsén 2007) and two
trials used aChattanooga Intelect Advanced combinationTherapy
System (Amer-Cuenca 2011; Keskin 2012).
Only three reports described both the intensity (i.e. subjective de-
scription) and current amplitude (mA) of TENS (Hruby 2006;
Liu 1985; Olsén 2007). Twelve reports described the intensity but
not current amplitude (Amer-Cuenca 2011; Cheing 2005; Coyne
1995; Crompton 1992;DeAngelis 2003; de Sousa 2014;Hansson
1983; Keskin 2012; Kim 2012; Oncel 2002; Ordog 1987; Roche
1985) and one report described pulse amplitude but not intensity
(Limoges 2004). Two trials delivered TENS using a fixed pulse
amplitude: Limoges 2004 used 30 mA; Olsén 2007 used 50 mA
in the high pulse amplitude TENS group and 10 to 15 mA in the
low pulse amplitude TENS group. Seven reports indicated that
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the pulse amplitude was adjusted during treatment (Amer-Cuenca
2011; Coyne 1995; De Angelis 2003; Gregorini 2010; Hansson
1983; Hruby 2006; Pitangui 2012). This information was un-
clear or not provided in the remaining trials. A variety of sub-
jective descriptors were used to describe the intensity of TENS
including: tingling, non-painful sensation from stimulated area
(high frequency TENS group) or non-painful muscular contrac-
tions in stimulated area (low frequency TENS group (Hansson
1983); strong but tolerable tingling (Amer-Cuenca 2011; Cheing
2005); subjective level of comfort (Liu 1985); highest level that did
not make participants uncomfortable (Oncel 2002); definite but
comfortable perception with no muscle activation (Roche 1985);
and below pain threshold (Coyne 1995). De Angelis 2003 used
the term ’tickle’ to describe the level of intensity. This is an unusual
term andmay be a result of translation fromnon-English language.
Most trials used high pulse frequencies, ranging from 51 Hz (Liu
1985) to 160Hz (Coyne 1995). Two trials used trains of pulses de-
livered at a low frequency (Hansson 1983; Roche 1985).One trial,
Ekblom 1987, had two TENS groups, one with a pulse frequency
of 2Hz and onewith a frequency of 100Hz. Pulse duration ranged
between 50 µs (Oncel 2002) and 400 µs (Amer-Cuenca 2011).
One trial used a pulse duration of 310 to 400 µs (Coyne 1995).
de Sousa 2014 reported using a pulse duration of 75 msec, which
seems excessively large. We suspect that this is a typographical er-
ror in the trial report as technical specifications for the device used
was listed as 45 to 300 µs by the manufacturer. Ordog 1987 did
not specify frequency or pulse duration settings.
There was a wide variation in the number of treatments and in-
dividual treatment times across the included trials. TENS was ad-
ministered in a single treatment session in 14 trials (Amer-Cuenca
2011; Coyne 1995; Crompton 1992; De Angelis 2003; de Sousa
2014; Ekblom 1987; Gregorini 2010; Hansson 1983; Hruby
2006; Kim 2012; Limoges 2004; Pitangui 2012; Roche 1985;
Olsén 2007) and in multiple treatment sessions in five trials
(Cheing 2005; Keskin 2012; Liu 1985;Oncel 2002;Ordog 1987).
Often it was difficult to ascertain exactly how often and for how
long TENS was administered in trials using multiple TENS treat-
ment sessions. Three of the seven reports of trials on procedu-
ral pain did not specify treatment duration (Crompton 1992; De
Angelis 2003; Hruby 2006); in those that did, treatment duration
varied from five minutes to four hours (Coyne 1995; Kim 2012;
Limoges 2004) or was described as being for the duration of the
procedure (Amer-Cuenca 2011). In the non-procedural pain tri-
als, treatment duration varied from one minute (Olsén 2007) to
applying TENS as often as required (Ordog 1987). Only two trials
involved TENS being self-administered at home where compli-
ance could be assessed (Oncel 2002; Ordog 1987). In these trials
participants continued to use TENS at home for two days (Oncel
2002) or used TENS at home for as long as needed with mean
duration of use being three days and no participants using TENS
at one month follow-up (Ordog 1987).
Comparison groups
Eleven trials included a placebo TENS intervention (Amer-
Cuenca 2011; Cheing 2005; Coyne 1995; Ekblom 1987;
Gregorini 2010;Hansson 1983;Hruby 2006; Kim2012; Limoges
2004; Ordog 1987; Roche 1985) and one trial included a placebo
pill (Oncel 2002). In most trials placebo TENS was opera-
tionalised as a shamTENS device with no current output that was
similar in appearance to the active TENS device but had no bat-
teries, or the internal circuit disconnected, or the device was not
switched on.Gregorini 2010 administered placeboTENSusing an
active device with an inter-pulse interval of 33 seconds and claimed
that this would avoid an analgesic effect. Liu 1985 applied a low
pulse amplitude stimulus (fixed at 2.5 mA) as they felt this was a
more valid control than a no stimulus placebo; for the purposes of
this review, this was treated as low pulse amplitude TENS rather
than placebo TENS. Only four of the trials that included placebo
TENS also included TENS naive participants. Coyne 1995 spec-
ified “no previous TENS exposure” as an inclusion criterion and
Cheing 2005 and Amer-Cuenca 2011 had previous experience
of TENS as an exclusion criterion. Ordog 1987 indicated that
none of their participants had used TENS previously. Olsén 2007
did not include a placebo group but did use TENS naive par-
ticipants. Eight trials included a no treatment comparison group
(Amer-Cuenca 2011; Coyne 1995; De Angelis 2003; de Sousa
2014; Hruby 2006; Keskin 2012; Limoges 2004; Pitangui 2012).
Four trials included a pharmacological intervention as a com-
parison group: acetaminophen (paracetamol; Keskin 2012); local
anaesthetic (Lignocaine withOctopressin, Crompton 1992); non-
steroidal anti-inflammatory drug (NSAID) (Naproxen Sodium;
Oncel 2002) and Tylenol (Ordog 1987). Two trials included a
non-pharmacological comparison group: exercise (Keskin 2012)
and vibration (Ekblom 1987). Two activeTENSgroupswere com-
pared by Ekblom 1987 (2Hz versus 100Hz); Hansson 1983 (con-
ventional TENS (100 Hz) to AL-TENS (2 Hz trains with 71 Hz
internal frequency); Olsén 2007 (high (50 mA) versus low (10 to
15 mA) pulse amplitude); and Liu 1985 (high (5.86 + 0.96 mA)
versus low (2.5 mA) pulse amplitude.
Adverse effects
Ten reports included information about the occurrence of adverse
effects with three indicating that there were no adverse effects
(Oncel 2002; Ordog 1987; Roche 1985) and seven indicating ad-
verse effects. De Angelis 2003 compared TENS with no treatment
in participants undergoing office hysteroscopy and reported nau-
sea (8.5% of TENS group; 11.3% of control group, sample size of
71 per group); shoulder pain (3% of TENS group; 0% of control
group); bradycardia (0% of TENS group; 2.8% of control group)
and dizziness (8.5% of TENS group; 10% of control group). They
did not specifically link these effects to TENS. Limoges 2004 re-
ported that 29 out of 30 participants in the TENS group and six
out of 30 participants in the placebo TENS group reported pain,
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burning or tingling at the electrode site. Hruby 2006 reported that
two out of 48 participants could not tolerate TENS and Keskin
2012 reported discomfort with the TENS treatment as an adverse
effect in one participant. Kim2012 reported erythema and itching
as adverse effects in seven out of 50 participants in the placebo
TENS group and eight out of 50 in the TENS group. Olsén 2007
reported that TENS was discontinued due to discomfort during
stimulation in one out of 13 participants receiving high pulse am-
plitude TENS. Hansson 1983 reported that most of the 20 par-
ticipants receiving low frequency TENS found muscle twitch un-
comfortable.
Outcomes
All trials used standard pain scales/questionnaires to record pain
(VAS; NRS; McGill Pain Questionnaire, MPQ; VRS) but many
trials did not provide sufficient information about the exact in-
struction given to participants about how to rate pain scores. Thus,
it was difficult to determine whether pain scores were taken at
a specific moment in time (e.g. present pain intensity) or retro-
spectively for over a specified period of time (e.g. pain intensity
for the previous 24 hours) and if taken retrospectively whether
scores were for ’average’ pain or worst pain episode. Other out-
comes included time inminutes until first report of pain reduction
and maximum pain reduction (Hansson 1983), overall impres-
sion of using TENS (de Sousa 2014; Liu 1985), discomfort dur-
ing TENS (Amer-Cuenca 2011; Crompton 1992; de Sousa 2014;
Olsén 2007). One trial used a RolandMorris Disability Question-
naire (Keskin 2012). It was only possible to ascertain that three
trials measured pain intensity whilst TENS was switched on and
generating an electrical paraesthesia (Amer-Cuenca 2011; Ekblom
1987; Hruby 2006). Amer-Cuenca 2011 measured pain intensity
during non-sedated colonoscopy; Ekblom 1987 measured pain
intensity in participants experiencing acute dental pain due to pul-
pal inflammation, apical periodontitis, pericoronitis or postoper-
ative pain following operative removal of an impacted tooth; and
Hruby 2006measured pain intensity during TENS for discomfort
during office-based flexible cystoscopy. Many trials recorded pain
after TENS had finished.
Excluded studies
For this update we retrieved 1065 reports from the literature
searches after we removed duplicates, of whichwe considered 1038
irrelevant or excluded against eligibility criteria based on screening
of abstracts (Figure 1). We obtained 24 full-text trial reports, of
which we excluded 17. Overall we excluded 120 trials on the basis
that TENS was given in combination with another treatment as
part of the formal trial design, of which 73 were postoperative
pain trials (Table 1). Inmost trials, TENSwas given with analgesic
medication as part of the formal trial design but some provided
TENS in conjunction with non-pharmacological interventions,
e.g. TENS given as part of a physiotherapy package of treatment.
The reasons for excluding the remaining trials included not using
a standard TENS device or TENS intensity in the active interven-
tion was too low (Characteristics of excluded studies).
Studies awaiting classification
Eleven trials are awaiting classification (Characteristics of studies
awaiting classification). Nine were written in English (Cambiaghi
2013; França 2012; Hsueh 1997; Liebano 2013; Park 2014;
Rajpurohit 2010; Treacy 2011; Salvino 2013; Silva 2012) and two
in Portuguese that required translation (de Paiva Tosato 2007;
Salvador 2005). We contacted the trial authors by e-mail to clarify
their eligibility based on three of our inclusion criteria (i.e. if the
trial involved acute pain, if it was a randomised trial, or if other
treatment was given in addition to TENS). The full trial report
of the abstract by Liebano 2013 has been submitted for publica-
tion. We have not obtained the information required to classify
the other studies yet.
Risk of bias in included studies
The ’Risk of bias’ table provides details of judgements on the
following items: allocation; blinding; incomplete outcome data;
and, sources of funding bias. We have provided the overall ’Risk of
bias’ assessment of the 19 trials in Figure 2. We have listed details
of the judgments about each methodological quality item for each
included trial in Figure 3.
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Figure 2. Methodological quality graph: review authors’ judgments about each methodological quality item
presented as percentages across all included studies.
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Figure 3. Methodological quality summary: review authors’ judgments about each methodological quality
item for each included trial.
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Allocation
We considered sequence generation to be adequate in 11 tri-
als (Amer-Cuenca 2011; Cheing 2005; Coyne 1995; De Angelis
2003; de Sousa 2014; Keskin 2012; Limoges 2004; Olsén 2007;
Oncel 2002; Ordog 1987; Pitangui 2012), and unclear or inad-
equate in the other eight trials. Six trials used a computer gener-
ated list for sequence generation (Amer-Cuenca 2011; De Angelis
2003; de Sousa 2014; Olsén 2007; Oncel 2002; Pitangui 2012).
Ordog 1987 mixed active and sham TENS devices during allo-
cation and unblinded group allocation when all devices were re-
turned to the researcher after the trial was completed. Gregorini
2010 used a ’sealed’ box for randomisation but did not give specific
operational details. Coyne 1995 and Keskin 2012 used a randomi-
sation table.We rated the remaining trials as either inadequate (di-
viding participants alternatively into groups; Liu 1985) or unclear
in their methods of sequence generation (Ekblom 1987; Gregorini
2010; Kim 2012). Only three trials had adequate allocation con-
cealment (Keskin 2012; Olsén 2007; Ordog 1987). Olsén 2007
and Keskin 2012 were the only trials to use pre-sealed opaque
envelopes. Ordog 1987 revealed which of the TENS units were
active or sham only after they had been returned to the researcher
when the trial was completed. Most trials were unclear regarding
how allocation was concealed (Amer-Cuenca 2011; Cheing 2005;
Coyne 1995; Crompton 1992; De Angelis 2003; de Sousa 2014;
Gregorini 2010; Hansson 1983; Hruby 2006; Kim 2012; Oncel
2002; Pitangui 2012; Roche 1985) and deemed inadequate in two
trials (Limoges 2004; Liu 1985).
Blinding
Participant blinding
It is impossible to fully blind participants to an electrical current
that generates a sensory experience, although participants can be
made to be uncertain whether the sensations that they experience
are likely to be effective. Four trials that included a placebo control
specified that participants were TENS naive (Amer-Cuenca 2011;
Cheing 2005; Coyne 1995; Ordog 1987). Studies that used a
shamTENS device ensured that it was similar in appearance to the
active TENS device but delivered no current (Amer-Cuenca 2011;
Cheing 2005; Coyne 1995; Hansson 1983; Hruby 2006; Kim
2012; Limoges 2004; Oncel 2002; Ordog 1987; Roche 1985) or
a very low pulse amplitude current (Liu 1985; Gregorini 2010).
In addition, participants were told they may or may not feel a
sensation during the treatment (Cheing 2005; Kim2012; Limoges
2004; Oncel 2002; Roche 1985) or that some people may not
experience the stimulation (Hansson 1983). Olsén 2007 did not
use a placebo TENS intervention and participants experienced
TENS sensation in both of the active TENS interventions.
Assessor blinding
In six trials, the person who recorded the outcomes was blind
to group allocation (Amer-Cuenca 2011; Cheing 2005; Coyne
1995; Kim 2012; Liu 1985; Ordog 1987). Five trials did not have
blinded assessors (de Sousa 2014; Hansson 1983; Limoges 2004;
Olsén 2007; Oncel 2002). Oncel 2002 recorded pain scores using
an investigator not blinded to group allocation and also by nurses
who were blinded to group allocation. The remaining trials did
not provide sufficient details to judge assessor blinding (Crompton
1992; De Angelis 2003; Ekblom 1987; Gregorini 2010; Hruby
2006; Keskin 2012; Pitangui 2012).
Follow-up and exclusions
Amer-Cuenca 2011, Kim2012, Limoges 2004, Pitangui 2012 and
Roche 1985 did not report any participant withdrawals. de Sousa
2014 evaluated 44 participants for eligibility, of which five did not
meet the inclusion criteria, six were excluded and one refused to
participate in the trial. All 32 participants randomised completed
the trial. Coyne 1995 withdrew ten participants post-randomi-
sation as they did not meet blood donor criteria, although such
screening for eligibility should have been conducted before ran-
domisation. Crompton 1992 provided details of two withdrawals
(one participant failed to record a pain score and another found the
cervical laser treatment uncomfortable) but there were no details
of which treatment group they belonged to. Oncel 2002 reported
that eight participants were withdrawn due to complications from
respiratory distress associated with their minor rib fractures but
they did not state which treatment group they belonged to. These
withdrawals were replaced. Liu 1985 reported the number of par-
ticipants that data were recorded from on each postoperative day
but did not give specific reasons for the incomplete data set. Olsén
2007 reported that one participant dropped out due to discomfort
of TENS (high pulse amplitude TENS group). Keskin 2012 re-
ported dropouts due to non-compliance, loss to follow-up or preg-
nancy-related complications but gave no information on how this
data was dealt with. Six trials did not provide details on whether
there were any incomplete data (Cheing 2005; De Angelis 2003;
Gregorini 2010; Hansson 1983; Hruby 2006; Ordog 1987).
Other potential sources of bias
There was a high risk of bias associated with inadequate sample
sizes in treatment arms. Four trials acknowledged sources of fund-
ing: loan of TENS units from a TENS manufacturer (Crompton
1992); TENSunits provided by aTENSmanufacturer anduniver-
sity project grant (Limoges 2004); research foundation (Hansson
1983); and a research council grant (Roche 1985). None of these
sources were thought to introduce bias.
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Effects of interventions
Primary objective
The primary objective of this Cochrane Review was to assess the
analgesic effectiveness of TENS, as a sole treatment, for acute pain
in adults. We were unable to extract data from included trials for
the following reasons: data presented as median and interquar-
tile (IQ) range (Crompton 1992; Keskin 2012); insufficient data
provided (Coyne 1995). We felt that there was sufficient infor-
mation in reports to assume that De Angelis 2003 and Hruby
2006 presented means with standard deviations (SDs). We also
decided to extract data from the two trials that included at least
one participant under 16 years (age range: Cheing 2005 = 15 to
58 years; Oncel 2002 = 11 to 81 years) because the mean ages for
the sample populations were above 30 years. We contacted the fol-
lowing authors in an attempt to obtain the data: Crompton 1992
(responded but unable to provide data as mean and SD); Coyne
1995 (responded but unable to provide data); Hruby 2006 and
DeAngelis 2003 (no response). There were insufficient extractable
data to allow us to pool data for meta-analysis for most planned
comparisons. We decided to pool data for pain intensity (100 mm
VAS) and proportion of participants achieving ≥ 50% reduction
in pain, although there was variability in procedures used to mea-
sure pain scores including whether scores were for present or ret-
rospective pain and whether TENS was switched on during pain
ratings.
TENS versus placebo TENS
Eleven trials included a comparison between active and placebo
TENS. Eight trials reported a statistically significant improvement
in favour of TENS of at least one outcome measure at one or more
time points (Amer-Cuenca 2011; Cheing 2005; Ekblom 1987;
Gregorini 2010; Hansson 1983; Kim 2012; Ordog 1987; Roche
1985). Cheing 2005 reported lower pain scores (VAS) for neu-
ropathic pain in the hand during TENS. Hansson 1983 claimed
that more patients experienced > 50% relief of orofacial pain post
treatment using a VAS but only reported details of a descriptive
analysis. Ordog 1987 reported a significant decrease in pain in-
tensity during TENS after two days of treatment (VAS, WMD -
2.44 cm, 95% CI -3.85 to -1.03, P = 0.0007). Roche 1985 re-
ported that more patients achieved 50% relief of pain associated
with haemophilia haemorrhage using TENS (P < 0.02). Ekblom
1987 reported that more patients experienced reduction of acute
orofacial pain using 100 Hz TENS following statistical analysis
using the Chi² test but there was insufficient information to eval-
uate the analysis. Gregorini 2010 reported a significant reduction
in post-operative pain intensity (VAS) following cardiac surgery
during TENS group (P < 0.001). Amer-Cuenca 2011 reported
that more patients achieved > 50% relief of pain associated with
colonoscopy during TENS (P < 0.001). Kim 2012 reported sig-
nificantly lower pain intensity (VAS) during venous cannulation
during TENS. Studies that reported no differences in pain out-
comes between TENS and placebo TENS found no significant
differences between active and placebo TENS for procedural pain
associated with venipuncture (Coyne 1995), flexible cytoscopy
(Hruby 2006) and flexible sigmoidoscopy (Limoges 2004). One
trial included a comparison between active TENS and placebo pill
and reported a statistically significant improvement in favour of
TENS (Oncel 2002).
We pooled data for pain intensity for six trials (seven comparisons)
but the I2 statistic (67%) suggested substantial heterogeneity (
Figure 4). The MD was -24.62 mm (95% CI -31.79 to -17.46;
six trials, 436 participants; Analysis 1.1) in favour of TENS using
a random-effects model. We pooled data for the proportion of
participants achieving ≥ 50% reduction in pain from four trials
(seven comparisons). The relative risk was 3.91 (95% CI 2.42 to
6.32; four trials, 280 participants; Analysis 1.2) in favour of TENS
with a NNTB of 2.49 (Figure 5). We were unable to pool other
data.
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Figure 4. Forest plot of comparison: 1 TENS versus placebo TENS, outcome: 1.1 Pain intensity (100 mm
VAS).
Figure 5. Forest plot of comparison: 1 TENS versus placebo TENS, outcome: 1.2 > 50% reduction in pain.
TENS versus no treatment control
Seven trials included a comparison between TENS and a no treat-
ment control. Five trials reported an improvement in favour of
TENS of at least one outcome measure at one or more time points
(Amer-Cuenca 2011; De Angelis 2003; de Sousa 2014; Keskin
2012; Pitangui 2012). de Sousa 2014 found that TENS reduced
post-partum uterine contraction pain during breast-feeding com-
pared with the no treatment control. De Angelis 2003 found that
TENS reduced the intensity of pain during hysteroscopy com-
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pared with a no treatment control. Amer-Cuenca 2011 reported
that more patients achieved > 50% relief of pain associated with
colonoscopy during TENS compared with a no treatment control.
Keskin 2012 reported that the pain intensity associated with LBP
during pregnancy was lower during TENS compared with a no
treatment control. Pitangui 2012 found a significant reduction in
resting, sitting and ambulating pain (NRS) following episiotomy
immediately after TENS and 60 minutes later when compared
with the control group (P < 0.001). Hruby 2006 found no signif-
icant differences between TENS and no treatment control for the
intensity of pain during flexible cytoscopy. Limoges 2004 found
no significant difference between TENS and no treatment control
groups during screening flexible sigmoidoscopy (NRS, WMD -
0.23 points, 95% CI -0.72 to 0.26, P = 0.36). We were unable
to ascertain whether Coyne 1995 used a no treatment control
or an unspecified ’placebo’ for procedural pain associated with
venipuncture. Coyne 1995 found no significant differences be-
tween TENS and the control/placebo.
We pooled data for pain intensity were pooled from five trials
(seven comparisons) but the I2 statistic value (71%) suggested
considerable heterogeneity (Figure 6). MD was -19.05 mm (95%
CI -27.30 to -10.79; five trials, 473 participants; Analysis 2.1) in
favour of TENS using a random-effects model. We were unable
to pool other data.
Figure 6. Forest plot of comparison: 2 TENS versus no treatment control, outcome: 2.1 Pain intensity (100
mm VAS).
TENS versus a pharmacological intervention
Four trials included a comparison between TENS and a phar-
macological treatment. Three trials reported an improvement in
favour of TENS of at least one outcome measure at one or more
time points. Crompton 1992 reported that TENS was superior
to local anaesthetic for procedural cervical laser treatment. Oncel
2002 reported that TENSwas superior toNSAID for rib fractures.
Keskin 2012 reported that TENS was superior to acetaminophen
(2 x 500mg/day) for LBP during pregnancy. Ordog 1987 reported
that there was no difference between TENS and acetaminophen
(300 to 600 mg) plus codeine (30 to 60 mg) for pain associated
with acute traumatic injuries including sprains, lacerations, frac-
tures, haematomas and contusions but did not make a direct com-
parison of TENS alone versus medication.We were unable to pool
other data.
TENS versus a non-pharmacological intervention
Two trials included a comparison between TENS and a non-phar-
macological treatment. Keskin 2012 reported that TENS pro-
duced greater pain relief than exercise for LBP during pregnancy.
Ekblom 1987 reported that there were no differences in pain relief
between TENS and vibration for acute orofacial pain. We were
unable to pool data.
Conventional TENS versus AL-TENS
Two trials included a comparison between conventional and AL-
TENS. Hansson 1983 and Ekblom 1987 reported that there were
no significant differences in the proportion of participants achiev-
ing > 50% reduction in orofacial pain between high frequency,
low intensity (conventional) TENS (100 Hz, intensity of two to
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three times perception threshold) and low frequency, high inten-
sity (acupuncture-like) TENS (2 Hz pulse train, intensity of three
to five times perception threshold). We pooled data for the pro-
portion of participants achieving ≥ 50% reduction in pain. The
relative risk was 0.72 (95% CI 0.37 to 1.39; two trials, 64 partic-
ipants; Analysis 3.1).
High pulse amplitude TENS versus low pulse amplitude
TENS
Two trials included a comparison between high and low pulse am-
plitude TENS. Olsén 2007 reported that high intensity (50 mA)
high frequency (70 to 100 Hz) TENS produced a larger decrease
in the intensity of pain associated with postpartum uterine con-
tractions than low intensity (15 mA) high frequency (70 to 100
Hz) TENS just above sensory detection threshold. The trial au-
thors reported a significantly higher number of participants re-
ported discomfort with the higher pulse amplitudes (P < 0.01).
Liu 1985 delivered active TENS at a “subjective level of comfort”
with a mean ± SD amplitude of 5.86 ± 0.96 mA across the sample.
For this analysis we interpret this ’high pulse amplitude’. They
also administered ’control’ TENS fixed at 2.5 mA as they believed
that this was a more valid control than a no stimulus placebo. For
the purposes of this Cochrane Review, we treated this as low pulse
amplitude TENS rather than placebo TENS. Liu 1985 found no
significant differences between these two pulse amplitudes (VAS,
WMD -1.53 cm, 95% CI -3.37 to 0.31; P = 0.1). In addition, De
Angelis 2003 measured pain intensity (VAS) during hysteroscopy
in one group of participants and reported that pain was reduced
to a greater extent when participants increased pulse amplitude
and associated intensity by pressing a ’plus’ switch on the device.
MD for these latter two trials was -23.47mm (95% CI -29.60 to
-17.34) in favour of high TENS using a random-effects model
(Analysis 4.1).
Secondary objectives
Insufficient extractable data meant that it was not possible to per-
form any planned subgroup analysis for any secondary objectives.
We were unable to determine whether TENS effectiveness was in-
fluenced by the time of recording the outcome measure, i.e. dur-
ing TENS measurement compared to post TENS measurement,
or to compare the duration of TENS treatment or comparisons
for different acute pain conditions.
D I S C U S S I O N
Summary of main results
This updated Cochrane Review examined the effectiveness of
TENS as a sole intervention for the treatment of acute pain in
adults. We retrieved 1065 reports from literature searches for this
update, in addition to the 1775 reports identified for the 2011
update. We included seven new trials and 11 studies are awaiting
classification. Thus, 19 RCTs involving 1346 participants at entry
met the inclusion criteria. We were able to extract data from 13
of the 19 included trials (Amer-Cuenca 2011; Cheing 2005; De
Angelis 2003; de Sousa 2014; Ekblom 1987; Hansson 1983; Kim
2012; Limoges 2004; Liu 1985; Olsén 2007; Oncel 2002; Ordog
1987; Roche 1985). Eight of 11 trial reports with a placebo TENS
comparison identified a statistically significant improvement in
favour of TENS of at least one outcome measures at one or more
measurement time point. Pooled data from six trials found a MD
of -24.62 mm (95% CI -31.79 to -17.46) on 100mm VAS in
favour of TENS. Pooled data from four trials (seven comparisons)
found a relative risk of 3.91 (95% CI 2.42 to 6.32), in favour of
TENS with a NNTB of 2.49 for the proportion of participants
achieving ≥ 50% reduction in pain. The NNTB is remarkably
low and most likely to have been exaggerated by the high risk of
bias associated with small sample sizes and various other biases as
highlighted in the risk of bias analysis. We do not attribute statisti-
cal credibility to the effect sizes because of statistical heterogeneity
but it is noteworthy that the direction of effect is consistent.
Five of the seven trial reports with a no treatment control identi-
fied an improvement in favour of TENS in at least one outcome
measure at one or more time point. Pooled data from five stud-
ies produced a MD of -19.05mm (95% CI -27.30 to -10.79) in
favour of TENS. Three out of four trials that compared TENS
with an analgesic drug and one out of two studies that compared
TENS with a non-pharmacological treatment found an improve-
ment in favour of TENS of at least one outcome measure at one or
moremeasurement time point. Three trials included a comparison
between high and low pulse amplitude and all found that higher
pulse amplitudes were superior. This finding is consistent with re-
cent experimental pain studies that indicated high pulse amplitude
(irrespective of the applied frequency) is the key parameter for ef-
fective TENS applications (Aarskog 2007; Chen 2008; Claydon
2008). Furthermore, a meta-analysis of TENS for postoperative
pain by Bjordal 2003 highlighted the relevance of optimal (strong
or maximal non-painful) intensity levels for pain relief in this clin-
ical population. There were no differences in the proportion of
participants achieving ≥ 50% reduction in pain between conven-
tional and AL-TENS in the two included trials. Three trial reports
indicated that there were no adverse effects and seven reports indi-
cated a range of adverse effects that were primarily related to sen-
sations experienced at the electrode site or the muscle contractions
associated with low frequency TENS. We judged these as minor.
The methodological quality of the trials varied considerably: we
judged sequence generation to be adequate in ten trials, allocation
concealment was adequate in three trials and only five had ade-
quate assessor blinding. There was a high risk of bias associated
with inadequate sample sizes with only two trials having sample
sizes ≥ 50 per treatment arm.
18Transcutaneous electrical nerve stimulation for acute pain (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Overall completeness and applicability of
evidence
The range of acute pain conditions included in this review was
limited by eligibility criteria that excluded trials of acute pain dur-
ing childbirth and primary dysmenorrhoea because these condi-
tions have been covered by previous Cochrane Reviews (Dowswell
2009; Proctor 2002). In addition, we excluded trials that evalu-
ated TENS in combination with any other treatment as part of
the formal trial design (e.g. analgesic medication, exercise) on the
basis that addition of another treatment would compromise pain
relief measures making it impossible to ascertain the contribution
of TENS. The highest number of excluded trials were on postop-
erative pain as they gave analgesicmedication in addition to TENS
for pain management. The effect of TENS in combination with
other treatments for acute pain is the subject for another system-
atic review. We categorised the 19 included trials into procedural
and non-procedural pain but were unable to pool data for sub-
group analyses. All trials were in the English language with most
based in Europe. Only one trial described the use of TENS by the
participants solely at home (Ordog 1987). As TENS can easily
be self-applied for most conditions, this limits the evidence for
comparison of self-applied versus therapist-applied TENS. The
range of outcome measures used provided limited data that could
be extracted from the included trials.
The reporting of TENS treatments showed wide variations across
the included trials. Several trials failed to report full details of the
TENS parameters used or technique of application, thus making
replication impossible. Attempts to combine outcomes in a meta-
analysis were undermined by substantial heterogeneity, a lack of
available data, and a lack of specific information on procedures
used to measure pain scores, especially whether scores were taken
for present pain or retrospective pain, during or after TENS. This
seriously limits the interpretation of the results. Both experimental
pain and clinical studies suggest that maximum pain relief is ob-
tained while TENS is switched on (Johnson 1991; Johnson 1999;
Tong 2007). Thus the timing of pain measurement is crucial, par-
ticularly for procedural pain; some included trials measured pain
post procedure but asked participants to record ’during procedure’
pain thus relying on recall (De Angelis 2003; Limoges 2004). Of-
ten it was impossible to ascertain the exact instruction given to
participants about the nature of the pain score required. As TENS
has been shown to havemaximum pain relieving effects during ap-
plication, it is important to record pain outcome whilst it is being
applied. Few trials continued to record the effect of TENS on pain
outcome for more than a few days thus limiting any conclusions
regarding the duration of effect of TENS on acute pain.
Quality of the evidence
The 19 included trials involved 1346 participants at entry. In gen-
eral, the quality of the evidence was weak due to inadequate meth-
ods or lack of information on: allocation concealment; blinding of
the outcome assessors; incomplete outcome data; and method of
analysis (per protocol or ITT). There was a high risk of bias from
inadequate sample sizes. Sample sizes ranged from eight to 71 per
group and nine trials had fewer than 20 participants in each treat-
ment arm. Only three trials had a prospective sample size calcula-
tion. Blinding participants to active TENS is challenging because
treatment necessitates a perceptual experience (i.e. TENS sensa-
tion) yet investigators should make every attempt to introduce
uncertainty about which treatment arm is active through care-
fully worded pre-trial instructions. TENS naïvety is an important
inclusion criteria in trials attempting to blind participants. Only
four of the trials that compared TENS to placebo used partici-
pants that were TENS naïve. Typically placebo TENS was admin-
istered using a sham TENS device with no electrical output and
no perceptual experience and this can be a credible approach to
achieve at least partial blinding (Deyo 1990). However, there was
no attempt in included trials to monitor the success or otherwise
of blinding using an assessment tool, such as that developed by
Deyo 1990. Rakel 2010 developed and tested a new sham TENS
device that delivered a current for 30 seconds, which then declined
in amplitude to 0 mA over 15 seconds. This output allowed the
clinician to set the pulse amplitude without knowing if the unit
was an active or sham device. Thus, the method of delivery of
treatment by the clinician was identical for each participant and
this type of sham TENS device may be useful for future trials.
Hrobjartsson 2007 highlighted this issue of monitoring blinding
in RCTs and analysed a random sample of 1599 blinded RCTs
indexed in CENTRAL and found that only 2% of trials included
tests for the success of blinding.
Potential biases in the review process
Review authors were not blinded from authors’ names, institu-
tions and journal name or trial results at any stage of the review
process. However, pairs of review authors undertook each stage of
the review process independently and we compared the outcomes.
Agreements and disagreements with other
studies or reviews
Cochrane Reviews on TENS for specific types of acute pain have
been inconclusive for labour pain (Dowswell 2009) and dysmen-
orrhoea (Proctor 2002).
A U T H O R S ’ C O N C L U S I O N S
19Transcutaneous electrical nerve stimulation for acute pain (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Implications for practice
In this update we identified seven additional trials to the 12 trials
reviewed in 2011. The analysis of 19 RCTs with 1346 participants
provides tentative evidence that TENS reduces pain intensity over
and above that seenwith placebo (no current) TENSwhen admin-
istered as a stand-alone treatment for acute pain in adults. How-
ever, the high risk of bias associated with inadequate sample sizes
in treatment arms and unsuccessful blinding of treatment inter-
ventions makes definitive conclusions impossible. The additional
analyses conducted in this second update strengthen evidence pre-
sented in Walsh 2009. Whether TENS should be considered as
a potential treatment option for patients and clinicians managing
acute pain remains a matter for debate, although TENS compares
favourably to many alternatives because it can be self-adminis-
tered, safe, inexpensive and readily available to patients over the
counter.
Implications for research
There was incomplete reporting of treatment in many reports,
making replication of trials impossible. Further adequately pow-
ered research trials are required to provide a comprehensive assess-
ment of the role of TENS as a sole treatment in acute painmanage-
ment. Bennett 2011 has provided criteria and operational guide-
lines for the design of a robust RCT on TENS. PaPaS guidance
suggests that a sample size of ≥ 200 participants per treatment
arm is necessary for a low risk of bias in RCTs. The Consolidated
Standards of Reporting Trials (CONSORT) statement has been
revised for non-pharmacological treatments (Boutron 2008); this
should be adopted to ensure better reporting of all aspects of trial
design and subsequent reporting. In particular, appropriate se-
quence generation and allocation concealment methods should be
used and reported. Sample size calculations should be performed
to determine appropriate participant numbers. Complete details
of the TENS application should be provided to allow subgroup
analysis between trials. Appropriate TENS technique should be
used including a strong non-painful TENS sensation at the site of
pain. A clear description of missing data and how they are analysed
is required. Outcome assessor blinding should be adopted as a key
element of future trial design. Blinding of participants is accepted
as a challenge in TENS trials but should be addressed nevertheless.
Finally, future trials should adopt a common policy of reporting
means and SDs for continuous data to enable data extraction for
subsequent meta-analysis.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Amer-Cuenca 2011
Methods Type of study: double-blind, placebo controlled RCT.
Condition and number of participants randomised: 90 participants attending for unse-
dated colonoscopy were randomised
Groups: TENS group 30; placebo TENS group 30; no-treatment control group 30
Participants Demographics: N = 90, mean age 50.2 years, TENS group mean age 49.5 years ± 2.4,
14F/16M; placebo group mean age 51.3 years ± 2.5, 19 female/11 male; control group
mean age 49.9 years ± 2.4, 17 female/13 male
Setting: outpatients.
Inclusion: attending unsedated screening colonoscopy, ASA I or II status, age > 18, no
visual or hearing impairments, no neuropsychiatric disorders
Exclusion: refusal to consent, non-Spanish speakers, colonic resection or stenosis of the
colon, previous experience of TENS, cutaneous damage on application sites, pacemaker
or cardiac defibrillator
Withdrawals/dropouts: no withdrawals.
Interventions Where applied: in hospital.
Applied by: not stated.
Waveform: not stated.
Frequency: 80 to 100 Hz.
Pulse duration: 400 µs.
Pulse amplitude/Intensity: adjusted to the maximum sensory level without muscle con-
traction
Placebo Group: procedures identical to those for TENS group, except that a sham unit
was used. Internal circuit of the shamTENS unit disconnected but the indicator lamp lit
when unit switched on. All participants told that they might or might not feel a tingling
sensation during treatment (Rx)
Electrodes: 2 rectangular autoadhesive electrodes, 7 cm x 13 cm, applied parallel to the
lumbo-sacral spine
Duration and frequency of Rx: for the duration of the procedure.
Device/manufacturer: Intellect Advance (Chattanooga)
Adverse effects: not detailed.
Outcomes Pain outcome: VAS, Likert Scale.
ITT/per protocol analysis: statistical analysis done according to ITT.
Statistical analysis: Intergroup and intragroup differences calculated using one-way
ANOVA for continuous variables, followed by Tukey’s post-hoc test and Chi² test for
proportional variables. Mean pain intensity VAS scores were no different from placebo
and control groups at 5 minutes. The active TENS group was significantly different at
5 minutes when compared against placebo or control groups (P < 0.001). At the end of
the procedure the TENS group VAS scores were significantly lower than the other two
groups (P < 0.001) The differences between the placebo and control groups were not
significant at 5 minutes and at the end
Spearman’s correlation coefficient between the VAS and Likert scales was performed.
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Amer-Cuenca 2011 (Continued)
There were significant differences when the TENS group was compared with either the
placebo or the control groups. The scores were significantly lower in the TENS group
compared with the other two groups (P = 0.009)
There was a strong correlation between VAS and Likert scales in measuring pain at both
5 minutes and at the end of the procedure (P < 0.001)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated block randomisation
with stratification for gender
Allocation concealment (selection bias) Unclear risk No details provided.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Not applicable - no withdrawals or drop-
outs.
Source of funding bias Low risk No funding bias apparent.
Blinding (Participant) Low risk TENS and Placebo participants blinded,
medics blinded.
Blinding (Outcome Assessor) Low risk Blinded assessor.
Sample Size High risk N = 30 per treatment arm.
Cheing 2005
Methods Type of study: double blind, placebo-controlled, parallel RCT.
Condition and number of participants randomised: clinical diagnosis of hypersensitive
hands due to peripheral nerve injuries (N = 19)
Groups: TENS group (N = 10); placebo group (N = 9).
Participants Demographics: N = 19, mean 35 yrs, range 15 to 58 yrs, 16 male/3 female. TENS group,
32 ± 11 yrs; placebo group, 38 ± 13 yrs (mean ± SD)
Setting: outpatients.
Inclusion: people who complained of hypersensitive hands within or adjacent to the site
of the injury, and who were able to complete the VAS independently
Exclusion: people who had general manifestations of pain as seen in causalgia or shoulder-
hand syndrome; people who had received any TENS or undergone a desensitization
programme 1month prior to the trial; cardiac pacemaker or who had experienced sensory
loss in their hands prior to the trial
Withdrawals/dropouts: not detailed.
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Cheing 2005 (Continued)
Interventions Where applied: in hospital.
Applied by: presume by clinician.
Waveform: square pulses.
Frequency: 100 Hz.
Pulse duration: 200 µs.
Pulse amplitude/Intensity: adjusted to produce a tingling sensation that was strong but
tolerable
Placebo Group: procedures identical to those for TENS group, except that a sham unit
was used. Internal circuit of the shamTENS unit disconnected but the indicator lamp lit
when unit switched on. All participants told that they might or might not feel a tingling
sensation during Rx
Electrodes: 2 rectangular carbon rubber electrodes with gel, 2 cm x 3 cm, anode applied
directly over the hypersensitive area and cathode placed proximally along the distribution
of the same peripheral nerve
Duration and frequency of Rx: 20 mins, 10 Rxs.
Device/manufacturer: 120Z TENS unit (ITO, Tokyo).
Adverse effects: not detailed.
Outcomes Pain outcome: pain intensity using VAS for a brush-evoked stimulus with a toothbrush.
Recorded before Rx on days 1, 4, 7 and 11
ITT/per protocol analysis: not detailed.
Statistical analysis: no evaluable data for this review as mixed age population (adults and
children). Significantly lower pain scores were found in the TENS group than in the
placebo group by Day 7 and Day 11. Both groups demonstrated significant decreases in
VAS scores across treatment sessions
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Subjects were matched by age, history
of developing hypersensitivity and baseline
VAS scores, and then randomly assigned
into either the TENS (n = 10) or placebo
group (n = 9) by drawing lots”
Allocation concealment (selection bias) Unclear risk No details provided.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details provided.
Source of funding bias Unclear risk No details provided.
Blinding (Participant) High risk It is impossible to adequately blind partic-
ipants who receive electrical stimulation
“All subjectswere blind to group allocation.
The placebo group had received no active
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Cheing 2005 (Continued)
treatment (just placeboTENS) throughout
the trial. The treatment procedures for the
placebo group were identical to those for
the real TENS group, except that a sham
unit was used. The appearance of the sham
unit was identical to that of a real TENS
unit, but the internal circuit of the sham
TENS unit was disconnected. When the
machinewas switched on, therewas noout-
put of current, but the indicator lamp lit
up. All subjects were told that they might
or might not feel a tingling sensation dur-
ing the treatment”
“People who had received any TENS” was
an exclusion criteria
Blinding (Outcome Assessor) Low risk “The blinded assessor repeatedly practiced
applying the same brushing force on a dig-
ital balance prior to the study”
Sample Size High risk TENS (N =10); placebo (N = 9).
Coyne 1995
Methods Type of study: double blind, placebo-controlled, parallel RCT.
Condition and number of participants randomised: procedural IV needlestick pain in
blood donors, 71.
Groups: TENS group (N = 19); placebo TENS group (N = 21); control group (N =
21), these are numbers after 10 participants were dropped due to not meeting Virginia
Blood Service criteria for blood donation
Participants Demographics: N = 71 randomised, 26 male/35 female post dropout. TENS group, 36
yrs; placebo TENS group, 37 yrs; control group, 35 yrs (mean)
Setting: blood donor clinic.
Inclusion: blood donors meeting Virginia Blood Service criteria for donation; previous
IV insertion; no previous TENS exposure; upper extremity exposure for electrode place-
ment; appropriate consent obtained; having venipuncture to the right or left antecubital
site
Exclusion: not detailed.
Withdrawals/dropouts: 10 participants were dropped as they did not meet the Virginia
Blood Service criteria for blood donation
Interventions Where applied: in clinic.
Applied by: clinician.
Waveform: balanced and biphasic.
Frequency: 160 pulses/s.
Pulse duration: 310 to 400 µs on the strength-duration mode.
Pulse amplitude/Intensity: below the participant’s pain threshold, adjusted during stim-
ulation to maintain this level
31Transcutaneous electrical nerve stimulation for acute pain (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Coyne 1995 (Continued)
Placebo TENS Group: TENS unit without batteries.
Control Group: no treatment.
Electrodes: 4 carbon electrodes, 4 cm, applied at site of venipuncture in a square fashion
Duration and frequency of Rx: min 12 mins and max 32 mins, 1 Rx.
Device/manufacturer: Maxima III TENS unit.
Adverse effects: not detailed.
Outcomes Pain outcome: pain assessed by a subjective and an affective VAS. Recorded before
intravenous (IV) insertion, after Rx, and at end of needle insertion phase
ITT/per protocol analysis: per protocol.
Statistical analysis: no evaluable data for this review as unable to extract data from paper.
No significant difference among groups for sensory or affective VAS scores
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “It was a convenient sample of 71 volun-
teer donors from the Virginia Blood Ser-
vice who were randomized into one of the
following three groups”
Author response “a randomization table
was how the participants were selected as
participants arrived and consented to the
trial”
Allocation concealment (selection bias) Unclear risk No details provided.
Incomplete outcome data (attrition bias)
All outcomes
Low risk “However, ten subjects were dropped be-
cause they did not meet the Virginia Blood
Service criteria for blood donation (i.e. low
haemoglobin)”
Source of funding bias Unclear risk No details provided.
Blinding (Participant) High risk It is impossible to adequately blind partic-
ipants who receive electrical stimulation.
“No previous TENS exposure” was an in-
clusion criteria. Author responded “both
were blinded” to the question “who was
blinded, was it the patient and person
recording VAS?”
Author response: “TENS unit without bat-
teries were the sham”
Control group received no treatment so
these participants could not be blinded
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Coyne 1995 (Continued)
Blinding (Outcome Assessor) Low risk Author responded “both were blinded” to
the question “who was blinded, was it the
patient and person recording VAS?”
Sample Size High risk TENS (N = 19); placebo (N = 21); control
(N = 21).
Crompton 1992
Methods Type of study: parallel RCT.
Condition and number of participants randomised: women undergoing cervical laser
treatment (N = 100). Two participants were excluded from analysis because they failed
to record pain score or found treatment too uncomfortable
Groups: TENS group (N = 34); local anaesthetic group (N = 35); TENS and local
anaesthetic group (N = 29)
NB 10 more participants recruited than initially intended as researchers lost count of
number recruited and failed to stop the trial
Participants Demographics: N = 100, all female. TENS group, 31.8 ± 9 yrs; local anaesthetic group,
32.6 ± 9 yrs; TENS and local anaesthetic group, 30.1 ± 8 yrs (mean ± SD)
Setting: colposcopy unit.
Inclusion: colposcopic diagnosis of cervical intra-epithelial neoplasia (CIN)
Exclusion: past history of treatment for CIN; other cervical surgery or pelvic inflamma-
tory disease; postmenopausal women; cardiac pacemakers
Withdrawals/dropouts: 1 woman excluded as she failed to record pain score. Another
found treatment too uncomfortable so direct local infiltration was added
Interventions Where applied: in hospital.
Applied by: clinician.
Waveform: not detailed.
Frequency: 80 Hz.
Pulse duration: 210 µs.
Pulse amplitude/Intensity: activated by participants under instruction, told to increase
it until it became uncomfortable
Electrodes: 4, conductive silicone polymer electrodes and gel, size not detailed. 2 applied
anteriorly to abdominal wall just above symphysis pubis, and 1 on each side of sacrum
Duration and frequency of Rx: participants given approximately 20 min to experiment
with TENS until they were called into another room for laser treatment. Duration of
TENS during laser treatment not detailed, 1 Rx
Device/manufacturer: Microtens (Neen Pain Management, UK).
Adverse effects: not detailed.
Outcomes Pain outcome: pain assessed by a VAS after the procedure. After procedure, participants
asked to complete questionnaire on TENS, one question was “did they find TENS pain
relieving?”
ITT/per protocol analysis: ITT.
Statistical analysis: no evaluable data for this review as data presented as medians and
IQ ranges. Median pain score for TENS group was significantly higher than that for
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Crompton 1992 (Continued)
local anaesthetic. Combining TENS with local anaesthesia did not further reduce the
median pain score. 51 women who used TENS completed questionnaire: of the coherent
responses 75% thought it was pain relieving
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Suitable subjects were then allocated to
one of the following three groups accord-
ing to a block randomised code”
It is unclear how this code was generated.
Allocation concealment (selection bias) Unclear risk “The block randomisation code was held
by one investigator who then allocated
treatment. The nurses, clerical officers re-
sponsible for the computerized appoint-
ments, and the laser surgeon did not have
access to this code”
It is unclear how this code was kept con-
cealed.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “One woman was excluded because she
failed to record pain score. Another
found the treatment too uncomfortable
and therefore direct local infiltration was
added”.No indicationwhat group these in-
dividuals were randomised to
“Fifty-one women who used TENS com-
pleted the questionnaire. Six responseswere
incoherent and nine women claimed the
treatment was not painful and they did not
need to turn the TENS on”. No indica-
tion what group these individuals were ran-
domised to
Source of funding bias Low risk “We are indebted to Roy Sherlock of Neen
PainManagement Systems (Old Pharmacy
Yard, Church Street, Dereham, Norfolk
NR161DJ) for lendingus theTENSunits”
Blinding (Participant) High risk “As it is impossible to conceal the use of
TENS from the attendants a sham instru-
ment was not used in group 3”
Groups were: TENS group; local anaes-
thetic group; TENS and local anaesthetic
group. There was no placebo group
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Crompton 1992 (Continued)
Blinding (Outcome Assessor) Unclear risk No details provided.
Sample Size High risk TENS (N = 24); local anaesthetic (N = 35)
; TENS and local anaesthetic (N = 29)
De Angelis 2003
Methods Type of study: parallel RCT.
Condition and number of participants randomised: participants undergoing office hys-
teroscopy, N = 142.
Groups: TENS group (N = 71); control group (N = 71).
Participants Demographics: N = 142, all female. TENS group, 47.9 ± 10 yrs; control group, 50 ± 10
yrs (mean ± SD)
Setting: gynaecological endoscopy centre.
Inclusion: outpatient hysteroscopy.
Exclusion: not detailed.
Withdrawals/dropouts: not detailed.
Interventions Where applied: in hospital.
Applied by: clinician.
Waveform: symmetric rectangular biphasic waveform.
Frequency: 100 pulses/s.
Pulse duration: 100 µs.
Pulse amplitude/Intensity: device set at basal level of stimulation, participant felt mild
tickle in area between electrodes. Participant instructed when she felt pain to gently press
plus switch once or several times. If feeling was unpleasant she could reduce amplitude
by pressing minus switch until discomfort disappeared
Control Group: no TENS applied.
Electrodes: 2, type and size not detailed, on abdomen in middle of line joining iliac
spine and pubic tubercle
Duration and frequency of Rx: during procedure, 1 Rx.
Device/manufacturer: Freelady TENS, Life Care, Tiberias, Israel.
Adverse effects: nausea, shoulder pain and dizziness reported in both groups, not specif-
ically linked to TENS
Outcomes Pain outcome: pain experienced during procedure assessed by VAS, after procedure.
For TENS group, pain at basal level of stimulation was compared with pain felt after
participant increased amplitude at least once
ITT/per protocol analysis: not detailed.
Statistical analysis: no evaluable data for this review as unclear if SD data are presented.
Significantly lower pain experienced during procedure by TENS group vs control group.
Within TENS group, pain at basal level of stimulation vs after participants had increased
amplitude at least once was significantly higher. Pelvic pain evaluated 5 mins after ex-
amination - significant reduction in TENS group vs control group
Notes
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De Angelis 2003 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A randomised, computer-generated list
was used to divide the subjects into two
equal groups (A and B) of 71 patients”
Allocation concealment (selection bias) Unclear risk No details provided.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details provided.
Source of funding bias Unclear risk No details provided.
Blinding (Participant) High risk It is impossible to adequately blind partic-
ipants who receive electrical stimulation.
No details provided. Groups were TENS
group and no treatment control group.
There was no placebo group. As the control
group received no treatment, these partici-
pants could not be blinded
Blinding (Outcome Assessor) Unclear risk No details provided.
Sample Size Unclear risk TENS (N =71); control (N =71).
de Sousa 2014
Methods Type of study: RCT.
Condition and number of participants randomised: 32 post-partummultiparous women
were randomised.
Groups: TENS group (N = 16); no-treatment control group (N = 16).
Participants Demographics: N = 32, mean age 26.84 ± 5.14 years.
Setting: hospital.
Inclusion: aged over 18 years, without post-partum complications, exclusively breast-
feeding, who experienced uterine contraction pain while breast-feeding. The women
were also literate and able to understand the pain rating scales used
Exclusion: intolerance to the stimulus generated by TENS or complications requiring
medical intervention, such as haemorrhage and infection
Withdrawals/dropouts: no withdrawals were reported.
Interventions Where applied: in hospital.
Applied by: not stated.
Waveform: asymmetrical.
Frequency: 100 Hz.
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de Sousa 2014 (Continued)
Pulse duration: 75 µs.
Pulse amplitude/Intensity: adjusted strong and tolerable sensation without muscular
contraction
Control Group: no TENS administered.
Electrodes: four 5 x 3 cm silicone and carbon rubber electrodes. Two electrodes were
placed in parallel in the T10-L1 region; the other two were placed in the S2-S4 region
Duration and frequency of Rx: 40 mins.
Device/manufacturer: KW Indústria Nacional de Tecnologia e Eletrônica, São Paulo,
Brazil
Adverse effects: not detailed.
Outcomes Pain outcome: numerical rating scale (NRS).
ITT/per protocol analysis: statistical analysis done according to ITT.
Statistical analysis: the Mann-Whitney U-test was used for comparison of pain between
the groups before and after application of TENS, and the Wilcoxon rank sum test for
intra group analysis. The results showed that the pain intensity of the uterine contraction
during breastfeeding in the TENS group showed a reduction of 2.00 compared with
0.69 in the control group. In both groups, the reduction of the intra group pain was
significant, as well as the inter group reduction. However, the assessment of the reduction
of pain in the TENS group showed clinically relevant pain relief, which was not obtained
in the control group. In addition, although the CG showed a significant reduction of
pain, it was not clinically significant
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation spreadsheet used - no fur-
ther detail available
Allocation concealment (selection bias) Unclear risk No details provided.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No dropouts or withdrawals reported.
Source of funding bias Unclear risk No details.
Blinding (Participant) High risk Patients would be aware that a no treatment
control was being used as comparison
Blinding (Outcome Assessor) High risk No details provided of any attempts to
blind assessor to group
Sample Size High risk TENS (N = 16); control (N = 16).
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Ekblom 1987
Methods Type of study: Randomised, placebo-controlled, parallel design.
Condition and number of participants randomised: acute pain from teeth or surrounding
tissues, N = 40.
Groups: 100 Hz Vibration Group (N = 8); placebo vibration group (N = 5); 2 Hz TENS
group (N = 11); 100 Hz TENS group (N = 11); placebo TENS group (N = 5)
Participants Demographics: N = 40, 20 to 58 yrs, 23 male/17 female.
Setting: emergency clinic for dental and oral surgery.
Inclusion: acute pain from teeth or surrounding tissues, or both.
Exclusion: not detailed.
Withdrawals/dropouts: not detailed.
Interventions Where applied: in clinic.
Applied by: presume by clinician.
Waveform: monopolar square wave pulses.
Frequency: high frequency (HF) group, 100 Hz; low frequency (LF) group, 71 Hz pulse
train (duration 84 ms) delivered at 2 Hz
Pulse duration: 0.2 ms.
Pulse amplitude/Intensity: HF set to produce a tingling sensation. LF set to produce
prominent muscular contractions
Placebo TENS Group: electrodes applied to skin but no stimulation transmitted. Par-
ticipants informed that some people might not experience the stimulation
Electrodes: two 3 cm x 3 cm conducting rubber, skin overlying painful area, anode distal
Duration and frequency of Rx: 30 min, 1 Rx.
Device/manufacturer: not detailed.
Adverse effects: not detailed.
Outcomes Pain outcome: VAS and 5 level verbal scale for pain intensity, before and after Rx. Heat
pain threshold recorded before, during and after Rx
ITT/per protocol analysis: not detailed.
Statistical analysis: no active stimulation was superior to the others re number of partic-
ipants reporting pain reduction; placebo significantly less effective than active stimula-
tion. No significant effects of Rx on heat pain threshold
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details provided.
Allocation concealment (selection bias) Unclear risk No details provided.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details provided.
Source of funding bias Unclear risk No details provided.
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Ekblom 1987 (Continued)
Blinding (Participant) Unclear risk Participants informed that theymay ormay
not experience a sensation associated with
treatment
Blinding (Outcome Assessor) Unclear risk No details provided.
Sample Size High risk 100 Hz Vibration (N = 8); placebo vibra-
tion (N = 5); 2 Hz TENS (N = 11); 100Hz
TENS (N = 11); placebo TENS (N = 5)
Gregorini 2010
Methods Type of study: placebo-controlled, parallel RCT.
Condition and number of participants randomised: postoperative period of cardiac
surgery (N = 25).
Groups: placebo group (N = 12); TENS group (N = 13).
Participants Demographics: N = 25, 59.9 ± 10.3 yrs (mean ± ?SD), 18 male/7 female.
Setting: inpatient.
Inclusion: patients aged between 35 to 80 years who had undergone elective cardiac
surgery via longitudinal median sternotomy
Exclusion: patients with pacemaker; pregnant women; cognitive or intellectual impair-
ment; absence of pain in the postoperative period; sensitivity disorders; and patients
undergoing any type of analgesia in the eight-hour period preceding the beginning of
the protocol
Withdrawals/dropouts: not detailed.
Interventions Where applied: in hospital.
Applied by: participant.
Waveform: not detailed.
Frequency: 80 Hz.
Pulse duration: 150 µs.
Pulse amplitude/intensity: participants adjusted the intensity of stimulation at the point
at which they felt a strong, although yet comfortable, prickling sensation, and were told
to reduce the intensity if they felt uncomfortable
Electrodes: 2 pairs of adhesive electrodes, 10 x 3.5 cm. Placed one on each side of the
surgical wound in the subclavian region
Duration and frequency of Rx: 4 hrs, 1 Rx.
Device/manufacturer: TENS Device, KLD, Amparo, São Paulo, Brazil.
Adverse effects: not detailed.
Outcomes Pain outcome: numerical VAS for pain intensity at rest and with cough, before and after
Rx
ITT/per protocol analysis: not detailed.
Statistical analysis: data were analysed usingmeans and SDs and non-parametric data was
analysed as medians and quartiles. Categorical data was expressed as absolute numbers
and relative (%) frequency). TENS significantly reduced pain in the postoperative period
with an improvement of 40% at rest and 42.9% with cough compared with the placebo
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Gregorini 2010 (Continued)
group. No statistical differences were found in the placebo group
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Use of “sealed box” for randomisation but
specific details not given
Allocation concealment (selection bias) Unclear risk No details provided.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details provided.
Source of funding bias Low risk No apparent funding bias.
Blinding (Participant) Unclear risk No details provided.
Blinding (Outcome Assessor) Unclear risk No details provided.
Sample Size High risk TENS (N =13); placebo (N = 12).
Hansson 1983
Methods Type of study: randomised, placebo-controlled, parallel design.
Condition and number of participants randomised: acute oro-facial pain (N = 62).
Groups: HF TENS group (N = 22); LF TENS group (N = 20); placebo TENS group
(N = 20)
Participants Demographics: N = 62, 19 to 54 yrs, 26 male/36 female.
Setting: emergency clinic for dental surgery.
Inclusion: acute oro-facial pain.
Exclusion: not detailed.
Withdrawals/dropouts: not detailed.
Interventions Where applied: in clinic.
Applied by: presume by clinician.
Waveform: monopolar square wave pulses.
Frequency: HF Group, 100 Hz; LF Group, 2 Hz, 71 Hz pulse train with total duration
of 84 ms delivered at 2 /sec
Pulse duration: 0.2 ms.
Pulse amplitude/Intensity: HF, adjusted to 2 to 3 times perception threshold to produce a
tingling non-painful sensation from the stimulated area. Output adjusted during TENS
in order to maintain a constant tingling sensation. LF, adjusted to 3 to 5 times perception
threshold which produced non-painful muscular contractions in the stimulated area
Placebo TENS Group: same as for other TENS groups except no batteries in units and
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Hansson 1983 (Continued)
participants told some people may not experience the stimulation
Electrodes: two, 2 cm x 3 cm conducting rubber, skin overlying painful area
Duration and frequency of Rx: 30 min, 1 Rx.
Device/manufacturer: CEFAR SIII, Lund, Sweden.
Adverse effects: most participants found the muscle twitches produced by LF TENS
uncomfortable
Outcomes Pain outcome: 5-graded verbal scale for pain intensity before Rx. VAS for pain intensity
before and after Rx. During Rx pain rated continuously using a graphic rating scale-
consistent results obtained with both methods. Time until first report of subjective pain
reduction and maximal pain reduction recorded
ITT/per protocol analysis: not detailed.
Statistical analysis: HF TENS: 7/22 reported pain reduction > 50%, includes 2 who
had total pain reduction. LF TENS: 9/20 reported pain reduction > 50%, includes 2
who had total pain reduction. Placebo TENS: 8/20 reported some degree of pain relief,
includes 2 who had pain reduction > 50%. In the two active TENS groups, approx 80%
reported a reduction of pain within less than 5 mins after onset of stimulation
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The patients were assigned randomly to
one of the three groups”
Allocation concealment (selection bias) Unclear risk No details provided.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details provided.
Source of funding bias Low risk “This work has been supported by grants
fromMagnus Bergwalls Stiftelse”. This is a
research foundation
Blinding (Participant) High risk It is impossible to adequately blind partic-
ipants who receive electrical stimulation.
“For practical reasons a double-blind tech-
nique could not be used.”
For the placebo TENS group: “Twenty pa-
tients received in all ways, except two, the
same treatment as the two groups receiving
TENS. One difference was that the TENS
stimulators used were not equipped with
batteries; and the other difference was that
these patients were told that some people
may not experience the stimulation”
The exclusion criteria were not provided so
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Hansson 1983 (Continued)
we do not know if participants had to be
TENS naïve
Blinding (Outcome Assessor) High risk Study appears to be designed as single blind
(i.e. participants blind)
Sample Size High risk HF TENS (N = 22); LF TENS (N = 20);
placebo TENS (N =20).
Hruby 2006
Methods Type of study: double blind, placebo-controlled, parallel RCT.
Condition and number of participants randomised: participants undergoing flexible
cystoscopy (N = 148).
Groups: active TENS group (N = 48); placebo TENS group (N = 49); control group
(N = 51)
Participants Demographics: N = 148, 108 male/40 female. Active TENS Group, 62.23 yrs; placebo
TENS Group, 61.53 yrs; control group, 60.98 yrs (? mean)
Setting: office-based.
Inclusion: flexible cystoscopy for surveillance of transitional cell carcinoma; voiding
symptoms; hematuria, or stent removal
Exclusion: participants with a neobladder; cystoscopy with biopsy or with dilation of
strictures; participants taking chronic analgesics or with pain syndromes; and participants
who required post procedure catheterization
Withdrawals/dropouts: not detailed.
Interventions Where applied: in hospital.
Applied by: clinician.
Waveform: symmetric rectangular biphasic.
Frequency: 100 pulses/s.
Pulse duration: 180 µs.
Pulse amplitude/Intensity: at the initial settings, the participant typically felt a slight
tickle at the site of the electrodes. The tickling sensation is greater than the sensory
threshold but less than the pain threshold. The starting point for pulse amplitude was
20 mA. During flexible cystoscopy, participants were able to change the amplitude on
the TENS device at will
Placebo TENS Group: unit identical to active unit but without any nerve stimulation
Control Group: no analgesia.
Electrodes: 2, type and size not detailed, each electrode was placed halfway along an
imaginary line drawn from the ASIS to pubis
Duration and frequency of Rx: duration not detailed, 1 Rx.
Device/manufacturer: Prometheus Group, Dover, NH.
Adverse effects: 2 participants in the Active TENS group could not tolerate the TENS
unit as the amplitude was gradually increased to the starting point of 20mA; 1 participant
in the Placebo TENS group reported severe abdominal pain several hours after the
procedure
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Hruby 2006 (Continued)
Outcomes Pain outcome: VAS, 30 seconds and 1 min into the procedure, 5 mins after procedure
finished
ITT/per protocol analysis: not detailed.
Statistical analysis: no evaluable data for this review as unclear if SD data are presented.
No significant changes in VAS between groups at each of the 3 time points
Notes Abbreviation: ASIS-anterior superior iliac spine
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “A total of 148 patients were prospectively
randomised into one of three groups.”
Allocation concealment (selection bias) Unclear risk No details provided.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details provided.
Source of funding bias Unclear risk No details provided.
Blinding (Participant) High risk It is impossible to adequately blind partic-
ipants who receive electrical stimulation.
Text says it was a double-blind study but no
details provided - assume they intended to
blind the participants. The placebo TENS
group was described as “a control group
with a placeboTENSunit (unit identical to
active unit but without any nerve stimula-
tion)”. The inclusion/exclusion criteria did
not state that participants had to be TENS
naïve. Control group received no treatment
so these participants could not be blinded
Blinding (Outcome Assessor) Unclear risk Text states that it was a double-blind study
but no details provided if the outcome as-
sessor was blinded
Sample Size High risk TENS (N = 48); placebo TENS (N = 49);
control (N = 51).
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Keskin 2012
Methods Type of study: prospective RCT.
Condition and number of participants randomised: 88 pregnant women suffering from
LBP with no previous history of LBP or lumbar pathology
Groups: active TENS (N = 22); exercise (N = 22); acetaminophen (N = 22); no-Rx
control (N = 22)
Participants Demographics: N = 88, all female. Age: TENS group 29.1yrs ± 5.0; exercise group 30.
7 ±4.3; acetaminophen 29.7 ± 4.2, control 29.2 ± 4.0
Setting: outpatient antenatal care unit, Turkey.
Inclusion: uncomplicated pregnancy with LBP.
Exclusion: history of Lumbar pathology pre-pregnancy or pathology detected during
physical examination; pain due to non-musculoskeletal factors; declined to take part
Withdrawals/dropouts: TENS (N = 2); exercise (N = 3); acetaminophen (N = 3); control
(N = 1)
Interventions Where applied: on the painful lumbar region.
Applied by: not stated.
Waveform: not stated.
Frequency: 120 Hz
Pulse duration: 100 µs
Pulse amplitude/Intensity: adjusted to produce a tingling sensation approx 2 to 3 times
above the sensory threshold
Placebo TENS Group: N/A.
Exercise group: completed a home exercise programme set by a physical therapist and
including pelvic tilting, stretching for the lower extremity and mild isometric abdominal
contractions x 10 of each per session, twice daily for 3 weeks
Acetaminophen group: one 500 mg paracetamol tablet 2 x daily for 3 weeks.
Control Group: no Rx administered
Electrodes: 4 surface electrodes 5 cm²
Duration and frequency of Rx: duration not stated. 2 sessions weekly for 3 weeks.
Device/manufacturer: Intelect TENS, Chattanooga Medical Supplies Inc., Taiwan).
Adverse effects: discomfort using TENS and gastric effect with medication.
Outcomes Pain outcome: VAS scores and Roland-Morris Disability Questionnaire (RMDQ)
ITT/per protocol analysis: not stated.
Statistical analysis: median pre-treatment VAS scores differed significantly between
groups (P = 0.004; Kruskal-Wallis test). These scores were significantly higher in the
TENS group (P = 0.002; post-hoc Mann-Whitney) and acetaminophen groups (P = 0.
009). Median pre-treatment RMDQ scores were similar across all groups. At the end of
the trial pain intensity had increased in control group (57%), and decreased in exercise
group(95%). In acetaminophen and TENS groups 100% had a decrease in pain. All
treatment groups showed a significant improvement in both VAS and RMDQ scores (P
< 0.0001) using the Wilcoxon test. Differences in pre and post-Rx VAS and RMDQ
scores were significant in all treatment groups using Kruskal Wallis (VAS; P < 0.001;
RMDQ, P < 0.001). This difference was caused by markedly higher scores in the TENS
group (P < 0.001 for both comparisons; Mann-Whitney test)
Notes
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Keskin 2012 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation using sealed envelopes.
Allocation concealment (selection bias) Low risk Use of sealed envelopes.
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawals and dropouts were reported
but no information was included as to how
the data was dealt with
Source of funding bias Low risk No apparent funding bias.
Blinding (Participant) High risk No TENS placebo group so not possible to
blind participants as to which group they
were allocated to
Blinding (Outcome Assessor) Unclear risk No details provided.
Sample Size High risk TENS (N = 22); exercise (N = 22); ac-
etaminophen (N = 22); control (N = 22)
Kim 2012
Methods Type of study: single-blind, placebo-controlled RCT.
Condition and number of participants randomised: 100 patients undergoing plastic
surgery.
Groups: 2 groups: active TENS (N = 50); placebo TENS (N = 50).
Participants Demographics: N = 100; TENS group 21 male/29 female; age 48.2 yrs ± 13.0; placebo
group 19 male/31 female; age 51.2 yrs ± 11.7
Setting: Hospital outpatient, Korea.
Inclusion: patients undergoing plastic surgery.
Exclusion: concomitant sedative or analgesic medication and neurological disease, or
potentially serious internal diseases (ASA physical status > 3)
Withdrawals/dropouts: none.
Interventions Where applied: radial side of the dominant forearm - cathode over cephalic vein 1cm
proximal to radial styloid process; anode 3 cm away proximal to cathode
Applied by: anaesthesiologist.
Waveform: not stated.
Frequency: 80Hz.
Pulse duration: 200 µs.
Pulse amplitude/Intensity: maximum tolerable level below pain threshold without no-
ticeable muscle contraction
Placebo TENS Group: TENS device without current output but with power indicator
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Kim 2012 (Continued)
light illuminated
Control Group: none.
Electrodes: 2 TensCare electrodes, 5 cm²
Duration and frequency of Rx: 20 minutes immediately prior to venous cannulation. 1
single Rx
Device/manufacturer: select TENS unit (Empi, St Paul, Minnesota).
Adverse effects: itching and erythema reported.
Outcomes Pain outcome: pain incidence; VAS scores.
ITT/per protocol analysis: not stated.
Statistical analysis: pain incidence was similar between the 2 groups (P > 0.05); 45 (90%)
in the TENS group experienced pain against 50 (100%) in the placebo group using the
X² test or Fisher exact test. Pain intensity (VAS) in TENS group was significantly lower
than placebo, with TENS VAS scores 1.9 ± 1.2 (P < 0.01) against placebo VAS scores 4.
8 ± 1.5 using Wlcoxon rank sum test with continuity correction
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details provided.
Allocation concealment (selection bias) Unclear risk No details provided.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated but nowithdrawals/dropouts re-
ported.
Source of funding bias Low risk No apparent funding bias.
Blinding (Participant) Low risk Placebo tens applied to blind participants.
Blinding (Outcome Assessor) Low risk “study-blinded anaesthesiologist”.
Sample Size Unclear risk TENS (N = 50); placebo TENS (N = 50).
Limoges 2004
Methods Type of study: double blind, placebo-controlled, parallel RCT.
Condition and number of participants randomised: participants undergoing screening
flexible sigmoidoscopy (N = 90)
Groups: TENS group (N = 30); placebo TENS group (N = 30); control group (N = 30)
Participants Demographics: N = 90, 51 male/39 female. TENS group, 57.18 ± 7.787 yrs; placebo
TENS group, 55.97 ± 5.411 yrs; control group, 58.6 ± 9.073 yrs (mean ± SD)
Setting: screening flexible sigmoidoscopy (SFS) speciality clinic.
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Inclusion: over 50 yrs; presenting for screening flexible sigmoidoscopy
Exclusion: cardiac pacemakers; automated implanted cardiac defibrillators; pre proce-
dural skin irritation at electrode placement site; pre procedural sedation or analgesia
Withdrawals/dropouts: not detailed.
Interventions Where applied: in clinic.
Applied by: clinician.
Waveform: biphasic waveform and asymmetric pulse pattern.
Frequency: 100 Hz.
Pulse duration: 190 µs.
Pulse amplitude/Intensity: 30mA, setting chosen after progressively increasing amplitude
and testing tolerability of each level on volunteers. Same intensity used for all participants
Placebo TENS Group: unit same as active group, attached to participant but not turned
on. All participants told they may or may not feel tingling sensation at electrode site
Control Group: received only verbal encouragement.
Electrodes: 4 self-adhesive, 2 x 5 inch rectangular, 2 on left upper and lower quadrants
of abdomen and 2 parallel to spinal cord at L1-S3 level
Duration and frequency of Rx: varied 5 to 15 mins, 1 Rx.
Device/manufacturer: Empi EPIX VT TENS.
Adverse effects: 29 participants in TENS group and 6 participants in placebo TENS
group reported pain/burning/tingling at electrode site
Outcomes Pain outcome: pain experienced during procedure assessed by a NRS of 1 to 5 for pain
intensity after procedure finished.
ITT/per protocol analysis: not detailed.
Statistical analysis: no significant difference between groups for pain experienced during
the procedure
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Author response: “Randomization was
done by drawing numbers out of a hat. We
picked a number out of the hat after the pa-
tient arrived and consented to participate”
Allocation concealment (selection bias) High risk Author response: “Randomization was
done by drawing numbers out of a hat. We
picked a number out of the hat after the pa-
tient arrived and consented to participate”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Ninety subjects were enrolled and com-
pleted the study”.
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Limoges 2004 (Continued)
Source of funding bias Low risk “Funding for this studywas provided by the
Innovative Pilot Project Grant Program at
the University of California Davis Medical
Center. The TENS unit was provided by
EMPI, Inc.”
Blinding (Participant) High risk It is impossible to adequately blind partic-
ipants who receive electrical stimulation
“Subjects in the sham TENS group were
connected to the TENS unit exactly the
same as subjects in the TENS group. The
research assistant manipulated the pro-
gramming buttons on the TENS unit ex-
actly as with the TENS group, but without
actually turning the TENS units on before-
hand. This step was performed in an ef-
fort to maintain blinding of both the endo-
scopist and subject. Subjects in the control
group received only verbal encouragement.
”
The inclusion/exclusion criteria did not
state that participants had to be TENS
naïve
Control group received no active treatment
so these participants could not be blinded
Blinding (Outcome Assessor) High risk Author response regarding the placebo
TENSgroup: “theTENSunitwas attached
to the subject but never turned on by the
RA (I and the subjectwere blinded to this)”.
“My RA administered the questionnaires”
Sample Size High risk TENS (N = 30); placebo TENS (N = 30);
control (N = 30).
Liu 1985
Methods Type of study: randomised, double blind, controlled, parallel design.
Condition and number of participants randomised: post thoracotomy, 30.
Groups: TENS group, 15; control group, 15.
Participants Demographics: N = 30, 18 to 72 yrs, 22 male/8 female. TENS group, 51.73 yrs; control
group, 52.73 yrs (mean)
Setting: hospital.
Inclusion: post thoracotomy.
Exclusion: participants who had cardiac surgery.
Withdrawals/dropouts: not detailed.
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Liu 1985 (Continued)
Interventions Where applied: in hospital.
Applied by: clinician.
Waveform: not detailed.
Frequency: mean was 75.75 Hz for TENS Group, 51 Hz for Control Group.
Pulse duration: 0.1 ms.
Pulse amplitude/Intensity: set at a subjective level of comfort, not adjusted during treat-
ment, mean pulse amplitude was 7.33 mA for TENS Group
Control Group: TENS applied at fixed pulse amplitude of 2.5 mA. All participants told
how TENS worked to control pain and what to expect from TENS after surgery
Electrodes: 2 carbon rubber and gel, size not detailed, placed on most painful area along
incision wound
Duration and frequency of Rx: 20 min, daily treatment from 1st post-op day until pain
disappeared or participant discharged or Rx rejected by participant
Device/manufacturer: HRS Neuro-Pulse Model HME-12.
Adverse effects: not detailed.
Outcomes Pain outcome: overall impression with TENS rated using 4 categories, after TENS
discontinued. Pain rated using a 0 to 10 scale before and after each TENS Rx. Recorded
daily (for 10 days) until pain disappeared, or patient discharged or treatment rejected by
the patient
ITT/per protocol analysis: not detailed.
Statistical analysis: significant alleviation of pain after TENS every day in the TENS
group. No significant change in the Control group except on days 4 and 6. Significant
difference between groups for post TENS pain scores on days 2/5/6/7/8
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Author response: “The patients were en-
rolled to the study consecutively before the
surgery, divided into experimental and con-
trol groups alternatively”. “Males and fe-
males were counted separately”
Allocation concealment (selection bias) High risk See under randomisation.
Incomplete outcome data (attrition bias)
All outcomes
High risk Table 2 gives pain scores on days 1 to 10.
The table details the number of participants
fromwhomdatawere recorded on each day
- shows a decline as the days progress. The
text says that stimulation was given every-
day from first postop day until pain disap-
peared, or the participant was discharged
or the treatment was rejected by the par-
ticipant. Table shows data collected for all
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participants (N = 15/group) for days 1 and
2 only. Figure 1 shows number of partic-
ipants in each group that continued with
TENS for each postop day. Specific rea-
sons for each participant not recording pain
scores was not given
Source of funding bias Unclear risk No funding source detailed.
Blinding (Participant) High risk It is impossible to adequately blind partic-
ipants who receive electrical stimulation
Author response: “The study design was
double blinded. The patients and I (the
evaluator) were blinded. All patients were
explained how TENS worked to control
pain and what the patient should expect
from TENS after operation”
The control group received low intensity
TENS.
The exclusion criteria were not provided so
we do not know if participants had to be
TENS naïve
Blinding (Outcome Assessor) Low risk Author response: “The study design was
double blinded. The patients and I (the
evaluator) were blinded”
Sample Size High risk TENS (N = 15); control (N = 15)
Olsén 2007
Methods Type of study: parallel RCT.
Condition and number of participants randomised: newly delivered women with pain
from postpartum uterine contractions (N = 21)
Groups: HI TENS group (N = 13); LI TENS group (N = 8).
Participants Demographics: N = 21, all female, 31 yrs (mean). HI TENS Group, 31 ± 4.2 yrs; LI
TENS Group, 31 ± 4.8 yrs (mean ± SD)
Setting: Department of Obstetrics and Gynecology.
Inclusion: newly delivered healthy women; well integrated in the Swedish language with
uncomplicated vaginal delivery; painful postpartum uterine contractions that required
pain relief
Exclusion: systemic disorders; abnormal pregnancy; operative delivery; other treatments
for the pain should not have been initiated
Withdrawals/dropouts: 1 in HI TENS group dropped out due to discomfort of stimu-
lation
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Interventions Where applied: in hospital.
Applied by: clinician.
Waveform: not detailed.
Frequency: 80 Hz.
Pulse duration: 0.2 ms.
Pulse amplitude/Intensity: HI, set at 50 mA. LI, set at just above the sensory threshold
(10 to 15 mA)
Electrodes: 2 carbon rubber and gel, 53 x 34 mm, placed on the lower part of the
abdomen, bilaterally over the uterus
Duration and frequency of Rx: 1 minute, 1 Rx repeated twice if no effect occurred.
Device/manufacturer: Cefar AB, Lund, Sweden.
Adverse effects: no adverse effects except for discomfort during stimulation were recorded
Outcomes Pain outcome: measurement of discomfort on a 5-point verbal scale, before and after
Rx. VAS for present pain intensity, before and after Rx. Discomfort of Rx recorded on
a 5-point verbal scale
ITT/per protocol analysis: not detailed.
Statistical analysis: median decrease in VAS pain ratings before and after treatment was
larger in the HI TENS group than in the LI TENS group. Post Rx, women in the HI
TENS group had less pain from the uterine contractions than the women in the LI
TENS group. HI TENS group experienced significantly less discomfort from uterine
contractions after treatment comparedwith the LITENS group.Discomfort fromTENS
itself was significantly greater in HI group than in LI group
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “After informed written consent, the
women were randomised to either high-in-
tensity (HI) or low intensity (LI) high-fre-
quency (80 Hz) TENS. The allocation se-
quence was determined before the study by
a research assistant using a computer gen-
erated random table.”
Allocation concealment (selection bias) Low risk “Groups were coded and the allocation
transferred to a series of pre-sealed opaque
envelopes.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “One patient in the HI TENS group
dropped out from the study immediately
after commencing TENS treatment be-
cause of discomfort of the stimulation.”
Source of funding bias Unclear risk No details provided.
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Blinding (Participant) Low risk Study described as single-blind. Groups
were high-intensity (HI) or low intensity
(LI) high-frequency (80 Hz) TENS. There
was no placebo TENS group
“Before treatment the women were in-
formed that they might experience pain or
discomfort from the electrical stimulation.
”
Author response: “it was the participants
who were blinded to the treatment”
Author response: “The patients had no pre-
vious experience of TENS”
Blinding (Outcome Assessor) High risk Study was designed as single blind.
Sample Size High risk HI TENS (N = 13); LI TENS (N = 8).
Oncel 2002
Methods Type of study: randomised, placebo-controlled, parallel design.
Condition and number of participants randomised: minor rib fractures, 100.
Groups: NSAID group, 25; TENS group, 25; NSAID and placebo TENS group, 25;
placebo tablets group, 25
Participants Demographics: N = 100, 11 to 81 yrs, 41 female/59 male, 40 ± 16 yrs (mean ± SD)
. NSAID group, 35 ± 19 yrs; TENS group, 44 ± 15 yrs; NSAID and placebo TENS
group, 41 ± 14 yrs; Placebo tablets group, 40 ± 16 yrs
Setting: hospital emergency service.
Inclusion: minor rib fractures.
Exclusion: 1st or 2nd rib fracture; more than 3 rib fractures or flail chest; requiring
hospitalisation for cranial or abdominal trauma; patient refusal; undergoing any kind of
surgery (including tube thoracostomy); cardiac or psychiatric illness; < 10 yrs; history of
gastrointestinal bleeding or ulcer or other contraindications for NSAIDS; being pregnant
Withdrawals/dropouts: 8 participants were excluded because of complications and
they were replaced. 7 had respiratory distress during the hospitalisation period; 3 had
haemothorax and 4 had pneumothorax. All were treated with tube thoracostomy. Right
haemothorax was diagnosed on the eighth patient the day after he had been discharged.
He was re-hospitalised and underwent a tube thoracostomy procedure
Interventions Where applied: in hospital and at home.
Applied by: clinician in hospital and by participant at home.
Waveform: not detailed.
Frequency: 80 Hz.
Pulse duration: 50 µs.
Pulse amplitude/Intensity: participants asked to turn up to the highest level that did not
make them uncomfortable
Placebo TENS Group: TENS unit without batteries and no sign on unit that showed
it was on. Participants in the TENS and NSAID and Inactive TENS group told they
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might or might not feel a sensation of tingling
Electrodes: 2 or 4 carbon rubber electrodes with adhesive gel, 3.4 x 4.2 cm, placed on
both sides of fractures along lines of intercostal nerves
Duration and frequency of Rx: 30 mins, 6 Rxs. 2 treatments in hospital: within 2 hrs
after admission and 12 hrs later. On discharge, home TENS twice a day for 2 days
Device/manufacturer: dual channel TENS, Biotens Inc Istanbul, Turkey.
Adverse effects: no complications seen during trial.
Outcomes Pain outcome: pain assessed by 0 to 10 scoring system. Recorded when hospitalised -
pre Rx, next day before they were discharged (after 2 phases of Rx) and third day after
therapy had ended
ITT/per protocol analysis: no.
Statistical analysis: no evaluable data for this review as mixed age population (adults
and children). Day 0: no significant difference between groups. Day 1: pain in placebo
group significantly higher than other groups. Pain in TENS group significantly less
than NSAID and NSAID and inactive TENS groups. Day 3: pain in TENS group
significantly less than all other groups and no significant difference between these 3
groups. All participants except the placebo group had significantly less pain on days 1
and 3 than day 0. In the placebo group, pain was significantly less on day 3 than 0 but
no difference between pain levels on day 0 and 1
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “One hundred consecutive patients admit-
ted to Kartal Education and Research Hos-
pital Emergency Service, were randomized
into four groups”
Author response: “A computerized ran-
domization protocol had been received
prior to the beginning of the trial, and the
randomization of the patients was done ac-
cordingly”
Allocation concealment (selection bias) Unclear risk No details provided.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “Eight patients were excluded because of
complications and they were replaced.
Seven had respiratory distress during the
hospitalisation period; three had haemoth-
orax and four had pneumothorax. All were
treated with tube thoracostomy. Right
haemothorax was diagnosed on the eighth
patient the day after he had been dis-
charged.Hewas re-hospitalized and under-
went a tube thoracostomy procedure”
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No indication which group these individ-
uals were randomised to
Source of funding bias Unclear risk No details provided.
Blinding (Participant) High risk It is impossible to adequately blind partic-
ipants who receive electrical stimulation
“These patients were told that they might
or might not feel a sensation of tingling,
and this instruction was carefully standard-
ized. The same blinded nurses performed
two phases of TENS therapy during the
hospitalisation period and instructed the
patients how to use the machine at home.
These nurses were told that every patient
would be treated with active TENS units
and that they were not to know about the
content of the trial. Inactive TENS units
were out of battery and there were no signs
on the machines that showed they were
’on’.’
Author response ‘As mentioned in the pa-
per, the patients were completely unaware
that the cases in the control group would
not feel a sensation, and both the patients
and the nurses assumed that all cases would
have a TENS treatment.”
The inclusion/exclusion criteria did not
state that participants had to be TENS
naïve
Blinding (Outcome Assessor) High risk Author response: “The pain scores were
recorded by one of the authors (HY) or by
educated nurses. The nurses were blinded
to the randomisation but the author was
not”
Not all of the outcome assessors were blind
to group allocation
Sample Size High risk NSAID (N = 25); TENS (N = 25); NSAID
and placebo TENS (N = 25); placebo
tablets (N = 25)
54Transcutaneous electrical nerve stimulation for acute pain (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ordog 1987
Methods Type of study: randomised, double blind, placebo-controlled, parallel design
Condition and number of participants randomised: acute trauma outpatients, 100.
Groups: functioning TENS group (N = 25); placebo TENS group (N = 25); functioning
TENS plus Tylenol (N = 25); placebo TENS plus Tylenol (N = 25)
Participants Demographics: N = 100, age/gender not detailed.
Setting: outpatients.
Inclusion: acute trauma outpatients.
Exclusion: < 21 yrs; hx cardiac disease or pacemaker; insufficient aptitude or personality
for operation of apparatus; allergies to acetaminophen or codeine; pregnancy
Withdrawals/dropouts: not detailed.
Interventions Where applied: at home by participant.
Applied by: participant.
Waveform: not detailed.
Frequency: not detailed.
Pulse duration: not detailed.
Pulse amplitude/Intensity: instructed to adjust energy knob to level at which pain dis-
appeared or until they felt a mild electric shock from the unit
Placebo TENS group: unit appeared like active but no electrical current transmitted to
the skin. It produced the slight hum and vibration that active unit produced. Participants
were not told that the functioning units could produce a mild electrical shock by turning
up the unit
Electrodes: 2 metal electrodes and a disposable sterile skin pad, size not detailed. Applied
over area of injury or as close to it as practical
Duration and frequency of Rx: could be worn at all times or as often as required for pain
control
Device/manufacturer: disposable TENS-PAC unit measures ½ x 3 x 4 inches. Dow
Corning, Arlington, Tennessee
Adverse effects: no complications and no side effects except a mild tingling sensation at
higher output levels, 20% of participants reported this effect
Outcomes Pain outcome: 11 point VAS for pain intensity, administered pre Rx, after two days of
Rx, and a month after initial injury
ITT/per protocol analysis: not detailed.
Statistical analysis: statistically significant reduction in pain severity in functioning TENS
vs placebo group at day 2, not at 1month. No significant difference between functioning
TENS unit and Tylenol group when either the subjective levels of pain versus time or
pre-Rx and post-Rx pain levels at 2 days and 1 month were compared. Mean length of
use of TENS in all groups was 3 days versus a mean of 5 days for the oral analgesics in
the 2 Tylenol groups
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk “One hundred consecutive consenting
acute trauma outpatients seen by the re-
searcher were randomly assigned to four
pain treatment groups. Randomization of
the TENS-PACunits was achieved bymix-
ing the two boxes of 50 functioning and 50
placebo units together. A decoding process
was released when all of the TENS-PAC
units were returned after the trial was com-
pleted. All of the units were returned to the
researcher following the trial to determine
which units the patient had and also to as-
sure their function”
Allocation concealment (selection bias) Low risk “A decoding process was released when all
of the TENS-PAC units were returned af-
ter the trial was completed. All of the units
were returned to the researcher following
the trial to determine which units the pa-
tient had and also to assure their function”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details provided.
Source of funding bias Unclear risk No details provided.
Blinding (Participant) High risk It is impossible to adequately blind partic-
ipants who receive electrical stimulation
“In the study, 50% of the patients received
a functioning TENS-PAC, and the other
50% received a ‘placebo’ unit, which ap-
peared and operated in all ways similar to
the functioning unit except that no electri-
cal currentwas transmitted to the skin.This
‘placebo’ unit was originally a functioning
TENS-PAC, but in this unit, an internal
wire that supplied the electrical current to
the skinwas cut. TheTENS-PACproduces
a slight humand vibration that the ‘placebo’
unit also produced. The ‘placebo’ units
were prepared by an independent source,
and neither the researcher nor the patient
was able to identify which unit was given
until the trial was completed. The possibil-
ity that the patients might have figured out
whether they had the placebo units seems
remote, as patients were not told that the
functioning units can produce a mild elec-
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trical shock by turning up the unit. As none
of the patients had used TENS previously,
it is unlikely that they would have known
that an electrical shock could be produced
only by the functioning units”
Blinding (Outcome Assessor) Low risk “The ’placebo’ units were prepared by an
independent source, and neither the re-
searcher nor the patient was able to identify
which unit was given until the study was
completed”
Sample Size High risk TENS (N = 25); placebo TENS (N = 25)
; TENS plus Tylenol (N = 25); placebo
TENS plus Tylenol (N = 25)
Pitangui 2012
Methods Type of study: RCT.
Condition and number of participants randomised: 40 primiparous women who had
experienced spontaneous vaginal delivery were randomised
Groups: N = 40, all female. HF TENS (N = 20), no-Rx control (N = 20)
Participants Demographics: all female (N = 40). Age 18 to 31 years (median 20.5 years) with no
statistical differences in age, education or colour between groups
Setting: hospital maternity ward, Brazil.
Inclusion: low-risk, primiparous pregnancy, older than 18 years of age, literate and
understanding of Portuguese language,aware of time and space, post-vaginal spontaneous
delivery, experienced an episiotomy with stitches, presenting with pain in the episiotomy
area, absence of any genitourinary pathology
Exclusion: contraindications to TENS, puerperal complications, previous exposure to
TENS, morbid obesity, instrumental delivery (e.g. use of forceps)
Withdrawals/dropouts: none reported
Interventions Where applied: parallel to the episiotomy site.
Applied by: not stated.
Waveform: biphasic, asymmetrical.
Frequency: 100 Hz.
Pulse duration: 75 µs.
Pulse amplitude/Intensity: strong numbing sensation but no muscle contractions.
Placebo TENS Group: N/A.
Control Group: no intervention received.
Electrodes: 4 silicone-carbon electrodes 5.5 cm x 3 cm.
Duration and frequency of Rx: 60 mins, single-session.
Device/manufacturer: Tens KW Compact, KW Industria Nacional Tecnologia e Elec-
tronica, San Paulo, Brazil
Adverse effects: none reported.
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Outcomes Pain outcome: numerical rating scale (NRS) 11 point (0 to 10) carried out at the begin-
ning of the trial (1st evaluation), at 60 mins (2nd evaluation) and 120 mins (3rd eval-
uation). Pain was measured during resting, sitting and ambulation at each evaluation.
McGill pain questionnaire used to obtain pain descriptors
ITT/per protocol analysis: not stated.
Statistical analysis: data for the groups were compared using the unpaired t-test and
intragroup differences analysed using a repeated-measures ANOVA with a post-hoc
Tukey test. Mann-Whitney test was used for analysing continuous variables such as
neonatal or obstetric data and Pearson’s Chi² test or Fisher’s exact test was used for
categorical variables. Groups presented similar pain scores at baseline. The application
of TENS significantly reduced pain intensity in resting, sitting and ambulating (P >
0.001) immediately after TENS and 60 mins later compared with the control group.
Comparing the 1st evaluation with the 3rd there was only a significant difference in the
TENS group
On the McGill pain questionnaire at baseline there were no significant differences. After
TENS there was a decrease in NWC (P > 0.001) in the TENS group and PRI for the
sensory, affective, evaluative, miscellaneous and total categories (P > 0.001). The TENS
group also showed a reduction in the NWC. The control group did not show a similar
alteration in the PRI or NWC
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated block randomisation
method.
Allocation concealment (selection bias) Unclear risk No details provided.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No withdrawals reported.
Source of funding bias Low risk No apparent funding bias.
Blinding (Participant) High risk No blinding.
Blinding (Outcome Assessor) Unclear risk No details provided.
Sample Size High risk HF TENS (N = 20); control (N = 20).
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Methods Type of study: placebo-controlled, parallel RCT.
Condition and number of participants randomised: haemophiliac participants (N = 36)
.
Groups: active TENS group (N = 28); placebo TENS group (N = 8).
Participants Demographics: N = 36, 35 ± 12 yrs (mean ± ?SD), gender not detailed.
Setting: specialised outpatient clinic at hospital.
Inclusion: haemophiliac participants suffering from unilateral haemorrhage into a joint
Exclusion: participants attending for dental care or for treatment to haemorrhage in the
region of the face, abdomen or cranium
Withdrawals/dropouts: none.
Interventions Where applied: in hospital.
Applied by: clinician.
Waveform: square wave pulses.
Frequency: internal pulse frequency of trains was 100 Hz and repetition rate of trains
was 5 Hz. In initial stage of trial, trains of pulses rather than continuous TENS reported
by participants as being more tolerable, consequently this form of TENS was adopted
throughout the trial
Pulse duration: 1 ms pulses, 100 ms train duration.
Pulse amplitude/Intensity: raised to a level of definite but comfortable perception with
no presence of muscle activation
Placebo TENS Group: as for active group but no stimulation applied. Participants in-
formed that a very high frequency of stimulation was being used which they might or
might not feel
Electrodes: 2 or 4, flexible carbon electrodes layered with electrode gel, 2x2 cm, over the
major sensory nerves supplying affected area or as close as possible to area of bleed
Duration and frequency of Rx: 25 min, 1 Rx.
Device/manufacturer: Digitimer Ltd, Model DS2.
Adverse effects: none.
Outcomes Pain outcome: MPQ (PRI, PPI, group scores for each category) before and after Rx for
current pain
ITT/per protocol analysis: no.
Statistical analysis: over 71% of participants receiving TENS reported changes in MPQ
scores which represented pain relief > 50%. Only 2 placebo participants (25%) reported
this amount of pain relief. The difference between participants reporting at least 50%
relief was significantly different between groups using PRI and PPI. 9 TENS participants
reported > 80% pain relief, 4 of these reported 100% pain relief. 2 placebo participants
reported > 50% pain relief, neither reported 100%. Pre Rx PRI data divided into mild-
medium (PRI score of 0 to 25) and medium-severe (PRI score of 26 to 50) based on
highest recorded PRI score of 50. For TENS participants, difference between these 2
groups of scores was not significant
Notes Abbreviation: MPQ- McGill pain questionnaire; PPI- present pain index; PRI- pain
rating index
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The subjects were randomly assigned to
one of two groups”.
Allocation concealment (selection bias) Unclear risk No details provided.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Trial author responded “no” to question
“Were there any dropouts/withdrawals?”
Source of funding bias Low risk “The research was supported by a grant
from The British Medical Research Coun-
cil (Grant No. 0979/723/N) awarded to K.
Gijsbers”
Blinding (Participant) High risk It is impossible to adequately blind partic-
ipants who receive electrical stimulation
Author response “The study was single
blind. The same researcher took measures
and applied TENS. Specific TENS settings
were screened from participants”
“The same apparatus and electrodes were
used for the placebo group, but no stimu-
lation was applied. These subjects were in-
formed that a very high frequency of stim-
ulation was being used which they might
or might not feel”
The exclusion criteria were not provided so
we do not know if participants had to be
TENS naïve
Blinding (Outcome Assessor) High risk Author response: “The study was single
blind. The same researcher took measures
and applied TENS. Specific TENS settings
were screened from participants”
Sample Size High risk N = 28 TENS; N = 8 placebo TENS
Characteristics of excluded studies [ordered by study ID]
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Study Reason for exclusion
Akhmadeeva 2010 RCT but chronic pain.
Andersen 2009a RCT but not a standard TENS device.
Andersen 2009b RCT but not a standard TENS device.
Barbarisi 2010 RCT but chronic pain.
Barker 2006 RCT but intensity too low.
Baskurt 2006 RCT but chronic pain.
Bertalanffy 2005 RCT but intensity too low.
Celik 2013 RCT but chronic pain.
Chee 1986 RCT but microcurrent used.
Coletta 1988 RCT but intensity too low.
Do u 2009 RCT but chronic pain.
Durmus 2009 RCT but chronic pain.
Ekblom 1985 RCT but TENS delivered at distal acupuncture point.
Eyigor 2012 RCT but chronic pain.
Fengler 2007 RCT but microcurrent used/chronic condition.
Gemmell 2011 RCT but ’latent’ myofascial trigger points used on otherwise asymptomatic adults
Gupta 2002 RCT but concurrent ’rescue’ medication given.
Gül 2009 RCT but chronic pain.
Herman 1994 RCT but not a standard TENS device.
Izadpanah 2005 RCT but needle electrode used/not standard TENS device.
Korkmaz 2010 RCT but chronic pain.
Kumar 2014 RCT but chronic pain.
Lang 2007 RCT but intensity too low.
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Lee 1997 RCT but not a standard TENS device.
Lee 2012 RCT but concurrent pain medication.
Leo 1986 RCT but mixed acute and chronic pain.
Mora 2006 RCT but intensity too low.
Murina 2008 RCT but chronic pain.
My liwiec 2011 RCT but chronic pain.
Peng-fei 2011 This is a letter a letter in response to study by Korkmaz et al which was excluded in first screening
because chronic pain
Pope 1994 RCT but not acute pain.
Reichstein 2005 RCT but H-wave device used.
Rodarti 2012 Duplicate of another study. Pitangui 2012
Rodríguez-Fernández 2011 Use of ’latent’ myofascial trigger points on otherwise asymptomatic individuals
Sahin 2011 RCT but chronic pain.
Solomon 1985 RCT but not a standard TENS device.
Stratton 2009 RCT but chronic pain.
Sunshine 1996 RCT but APS therapy used/chronic condition.
Taskaynatan 2007 RCT but IFT used.
Tsai 2010 RCT but chronic pain.
Tulgar 1991a RCT but chronic conditions included.
Tulgar 1991b RCT but chronic conditions included.
Wang 2009 RCT but chronic pain.
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Cambiaghi 2013
Methods Type of study: RCT.
Condition and number of participants randomised: 40 females submitted for office diagnostic hysteroscopy and
endometrial biopsy
Groups: active TENS with Tanyx and no-treatment control.
Participants Demographics: N = 40, female participants. Age not available.
Setting: Brazil.
Inclusion: information not available.
Exclusion: information not available.
Withdrawals/dropouts: information not available.
Interventions Where applied: infra-umbilical area.
Applied by: information not available.
Waveform: information not available.
Frequency: information not available.
Pulse duration: information not available.
Pulse amplitude/Intensity: information not available.
Electrodes: information not available.
Duration and frequency of Rx: information not available.
Device/manufacturer: information not available.
Adverse effects: information not available.
Outcomes Pain outcome: VAS for pain intensity, during Rx.
ITT/per protocol analysis: not detailed.
Statistical analysis: statistically significant reduction in VAS scores during both procedures in the TENS group
Notes
de Paiva Tosato 2007
Methods Type of study: parallel RCT.
Condition and number of participants randomised: temporomandibular pain (? acute pain), 20.
Groups: massage group, 10; TENS group, 10.
Participants Demographics: N = 20, 22 to 46 yrs, 31.75 ± 8.71 (mean ± SD), all female.
Setting: not detailed.
Inclusion: signs and symptoms of temporomandibular disorders; females.
Exclusion: no temporomandibular pain; males; dental problems; systemic disease; patients having other treatment
(dental treatment, physiotherapy, medication)
Withdrawals/dropouts: not detailed.
Interventions Where applied: not detailed.
Applied by: not detailed.
Waveform: not detailed.
Frequency: not detailed.
Pulse duration: not detailed.
Pulse amplitude/Intensity: participants told the sensation should be pleasant and were told to report whenever the
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intensity of the current decreased
Electrodes: not detailed. Placed over masseter muscle, anterior portion of temporal muscle
Duration and frequency of Rx: 30 min, 1 Rx.
Device/manufacturer: Quark.
Adverse effects: not detailed.
Outcomes Pain outcome: VAS for pain intensity, before and after Rx.
ITT/per protocol analysis: not detailed.
Statistical analysis: statistically significant reduction in VAS scores post Rx in both groups
Notes
França 2012
Methods Type of study: RCT.
Condition and number of participants randomised: 23 patients randomized into two groups.
Groups: TENS group, stabilization group (received exercises of lumbar segmental stabilization - transversus abdominis
and lumbar multifidus muscles exercises)
Participants Demographics: N = 23.
Stabilization group (SG N = 12; age 43.58 + 7.17; BMI 26.47 + 3.39)
TENS group (TG N = 11; age 46.45 + 5.14; BMI 26.92 + 3.02).
Setting: information not available.
Inclusion: information not available.
Exclusion: information not available.
Withdrawals/dropouts: information not available.
Interventions Both groups received 16 sessions, lasting 60 minutes, twice a week and evaluated before and after 8 weeks
TENS Group
Where applied: Information not available.
Applied by: information not available.
Waveform: information not available.
Frequency: information not available.
Pulse duration: information not available.
Pulse amplitude/intensity: information not available.
Electrodes: information not available.
Duration and frequency of Rx: 16 sessions, lasting 60 minutes, twice a week.
Device/manufacturer: information not available.
Adverse effects: information not available.
Outcomes Pain outcome: Visual Analog Pain Scale, Oswestry disability questionnaire for functional disability and pressure
biofeedback unit for the ability to contract the TrA muscle
ITT/per protocol analysis: information not available.
Statistical analysis: intragroup statistical analysis using t-test and Wilcoxon Signed Rank tests
“After eight weeks, Stabilization Group showed statistically significant improvement in pain (6.16+1.26; 1.58+1.
24; p<0.001), functional disability (15.50+3.77; 4.83+2.94; p<0,001) and the ability to contract the TrA muscle
(-0.83+1.49;-3.16+0.77; p<0,001). There was no statistically significant difference in TENS Group for functional
disability (18.09+4.27;17.09+7.96; p=0.569) and ability to contract the TrA muscle (-1.40+0.83; -1.54+0.93; p=0.
557), however it demonstrated improvement in pain (6.90+2.30;4.81+2.52; p=0.004)”
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Notes .
Hsueh 1997
Methods Type of study: randomised, double blind, placebo-controlled, parallel design
Condition and number of participants randomised: myofascial trigger points of upper trapezius muscle (? acute pain)
, N = 60
Groups: placebo group (N = 18); ENS group (N = 20); EMS therapy (N = 22)
Participants Demographics: N = 60, 44.4 ± 13.9 yrs (mean ± ?SD), 25 male/35 female. Placebo group, 41.4 ± 13.0 yrs; ENS
group, 42.7 ± 13.8 yrs; EMS therapy, 44.4 ± 14.5 yrs (mean ± ?SD)
Setting: outpatient clinic at hospital.
Inclusion: myofascial trigger points in one side of upper trapezius muscles
Exclusion: < 18 yrs or > 80 yrs; acute or serious illness; mental retardation; neurologic deficits involving the investigated
upper limb; advanced osteopathic or arthropathic disorder of the cervical spine or the shoulder of the investigated
side; participants should have had no therapy, such as physical therapy or injection therapy, within the last 2 months
on MTrPs selected for this trial
Withdrawals/dropouts: not detailed.
Interventions Where applied: in clinic.
Applied by: presume by clinician.
Waveform: not detailed.
Frequency: 60 Hz.
Pulse duration: not detailed.
Pulse amplitude/Intensity: at a level that the participant could feel but was not strong enough to induce muscle
contraction
Placebo Group: participant told that a certain type of therapy would be given to treat MTrPs, but was not told what
treatment was to be given. Electrodes were applied on the upper trapezius muscle as in other groups, 0 mA current
intensity
Electrodes: 2, type and number not detailed, negative electrode placed on MTrP of upper trapezius muscle and
positive one on its acromial tendon insertional site
Duration and frequency of Rx: 20 min, 1 Rx.
Device/manufacturer: not detailed.
Adverse effects: not detailed.
Outcomes Pain outcome: VAS for pain intensity, before and after Rx. PT of MTrP of the upper trapezius muscle before and
after Rx
ITT/per protocol analysis: not detailed.
Statistical analysis: improvement in PI and PT was significantly greater in the ENS Group than the other 2 groups
Notes ENS- electrical nerve stimulation; EMS- electrical muscle stimulation; MTrPs- myofascial trigger points; PI- pain
intensity; PT- pain threshold
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Liebano 2013
Methods Type of study: information not available.
Condition and number of participants randomised: information not available.
Groups: information not available.
Participants Demographics: N =74; gender and age not known.
Setting: information not available.
Inclusion: information not available.
Exclusion: information not available.
Withdrawals/dropouts: information not available.
Interventions Where applied: information not available.
Applied by: information not available.
Waveform: information not available.
Frequency: information not available.
Pulse duration: information not available.
Pulse amplitude/Intensity: information not available.
Electrodes: information not available.
Duration and frequency of Rx: information not available.
Device/manufacturer: information not available.
Adverse effects: information not available.
Outcomes Pain outcome: VAS for pain intensity, before and after Rx.
ITT/per protocol analysis: information not available.
Statistical analysis: information not available.
Notes
Park 2014
Methods Type of study: RCT.
Condition and number of participants randomised: 20 to 60 year-old women undergoing thyroidectomy.
Groups: control or TENS.
Participants Demographics: 20 to 60 year-old women undergoing thyroidectomy without history of headache or neck pain within
six months
Setting: information not available.
Inclusion: information not available.
Exclusion: information not available.
Withdrawals/dropouts: information not available.
Interventions TENS group
Intraoperative TENS.
Where applied: in the upper trapezius during thyroidectomy.
Applied by: information not available.
Waveform: information not available.
Frequency: information not available.
Pulse duration: information not available.
Pulse amplitude/Intensity: information not available.
Electrodes: information not available.
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Park 2014 (Continued)
Duration and frequency of Rx: information not available.
Device/manufacturer: information not available.
Adverse effects: information not available.
Outcomes Pain outcome: numerical rating scale of posterior neck pain and wound pain at 30 minutes, 6, 24 and 48 hours after
surgery
ITT/per protocol analysis: information not available.
Statistical analysis: information not available.
Notes
Rajpurohit 2010
Methods Type of study: randomised, controlled, parallel design.
Condition and number of participants randomised: bruxism with masticatory muscle pain (? acute pain), 60.
Groups: MENS group (N = 30); TENS group (N = 30).
Participants Demographics: N = 60, age not detailed, 36 male/24 female.
Setting: physiotherapy department in a hospital.
Inclusion: clinical diagnosis of bruxism; muscle tenderness over masseter muscle; early morning temporomandibular
joint stiffness and pain; duration of pain more than three weeks; and, age ranged from 19 to 60 years
Exclusion: wearing any removable restoration; treated with analgesic and antiinflammatory drugs; having muscle
pain without bruxism; presence of any tumour or cancer around jaws or infection
Withdrawals/dropouts: not detailed.
Interventions Where applied: in hospital.
Applied by: not detailed.
Waveform: not detailed.
Frequency: 50 Hz.
Pulse duration: 0.5 ms.
Pulse amplitude/Intensity: intensity was as per the participant’s tolerance.
Electrodes: carbon electrodes, number not detailed, 40 x 54 mm2. Placed over the affected side of masseter muscle.
Duration and frequency of Rx: 20 minutes, 1 Rx daily for 7 days.
Device/manufacturer: not detailed.
Adverse effects: not detailed.
Outcomes Pain outcome: VAS for pain intensity, pre-TENS and post-TENS at the end of the 7th day of treatment. Tenderness
by using digital pressometer of 2 KgF, pre-TENS and post-TENS at the end of the seventh day of treatment
ITT/per protocol analysis: not detailed.
Statistical analysis: statistically significant pain relief and decrease in tenderness in MENS group compared to TENS
group
Notes
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Salvador 2005
Methods Type of study: Randomised, blinded, controlled, parallel design.
Condition and number of participants randomised: acute LBP, 28.
Groups: muscle energy technique group (N = 14); TENS group (N = 14)
Participants Demographics: N = 28, age not detailed, all male.
Setting: clinic.
Inclusion: acute LBP (constant pain present for no more than 3 weeks); shortening of at least one of the muscle
groups assessed; no treatment (physiotherapy or tablets) in the last 2 weeks for the LBP
Exclusion: chronic LBP; rheumatological problems (arthritis, osteoporosis); no muscle shortening; positive Valsalva
Withdrawals/dropouts: not detailed.
Interventions Where applied: in clinic.
Applied by: clinician.
Waveform: not detailed.
Frequency: not detailed.
Pulse duration: not detailed.
Pulse amplitude/Intensity: not detailed.
Electrodes: not detailed.
Duration and frequency of Rx: 5 min, 1 Rx.
Device/manufacturer: Quark.
Adverse effects: not detailed.
Outcomes Pain outcome: VAS for pain intensity, before and after Rx.
ITT/per protocol analysis: not detailed.
Statistical analysis: significant reduction in pain intensity after treatment in TENS group when compared to muscle
energy technique group
Notes
Salvino 2013
Methods Type of study: randomised, placebo controlled.
Condition and number of participants randomised: 145 consecutive headache sufferers grouped in 2 groups according
to cutaneous allodynia total score
Groups: real or sham TENS.
Participants Demographics: information not available.
Setting: information not available.
Inclusion: information not available.
Exclusion: information not available.
Withdrawals/dropouts: information not available.
Interventions TENS group
Where applied: at the back of the head bilaterally.
Applied by: information not available.
Waveform: information not available.
Frequency: information not available.
Pulse duration: information not available.
Pulse amplitude/Intensity: information not available.
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Salvino 2013 (Continued)
Electrodes: information not available.
Duration and frequency of Rx: 30 minutes, three times a day for two consecutive weeks.
Device/manufacturer: information not available.
Adverse effects: information not available.
Sham TENS group: information not available.
Outcomes Pain outcome: number of headache free-days (> 50%) at 15, 30 and 60 days.
ITT/per protocol analysis: information not available.
Statistical analysis: information not available.
“A significant change in number of headache free-days above 50% was observed in 53 (49%) out of l08 patients
treated with real TENS. Of these patients thirty-seven respondents (82%) were non allodynic. While 47 (75%) out
of the 63 non respondents were allodynic patients. Only 2 (5%) out of the 37 patients were responsive to sham
TENS therapy.”
Notes Objectives: to test if cutaneous allodynia influences the response to treatment with TENS in headache sufferers
Silva 2012
Methods Type of study: single-blind, randomised design.
Condition and number of participants randomised: patients post-laparoscopic cholecystectomy (N = ?).
Groups: active TENS and placebo TENS.
Participants Demographics: N = ? Age and gender not available.
Setting: not available.
Inclusion: not available.
Exclusion: not available.
Withdrawals/dropouts: not available.
Interventions Where applied: information not available.
Applied by: information not available.
Waveform: biphasic square pulse TENS current.
Frequency: 150 Hz.
Pulse duration: 75 µs.
Pulse amplitude/Intensity: information not available.
Electrodes: information not available.
Duration and frequency of Rx: information not available.
Device/manufacturer: information not available.
Adverse effects: information not available.
Outcomes Pain outcome: VAS for pain intensity, post Rx.
ITT/per protocol analysis: information not available.
Statistical analysis: statistically significant reduction in VAS scores post Rx in active TENS group
Notes
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Treacy 2011
Methods Type of study: randomised, placebo controlled design (pilot study).
Condition and number of participants randomised: 12 adults admitted for IV antibiotics with acute lung pain (VAS
score > 4/10)
Groups: active TENS and placebo TENS
Participants Demographics: N = 12; age and gender information not available.
Setting: Northern Ireland; hospital inpatient setting.
Inclusion: TENS naive.
Exclusion: information not available.
Withdrawals/dropouts: information not available.
Interventions Where applied: information not available.
Applied by: information not available.
Waveform: information not available.
Frequency: 150 Hz.
Pulse duration: 200 ms.
Pulse amplitude/Intensity: information not available.
Electrodes: Information not available.
Duration and frequency of Rx: the duration of the lung pain.
Device/manufacturer: information not available.
Adverse effects: information not available.
Outcomes Pain outcome: VAS for pain intensity, before and after Rx.
ITT/per protocol analysis: not detailed.
Statistical analysis: statistically significant reduction in VAS scores post Rx in both groups
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. TENS versus placebo TENS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain intensity (100 mm VAS) 6 436 Mean Difference (IV, Random, 95% CI) -24.62 [-31.79, -17.
46]
2 > 50% reduction in pain 4 280 Risk Ratio (M-H, Fixed, 95% CI) 3.91 [2.42, 6.32]
Comparison 2. TENS versus no treatment control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain intensity (100 mm VAS) 5 473 Mean Difference (IV, Random, 95% CI) -19.05 [-27.30, -10.
79]
Comparison 3. Conventional TENS versus AL-TENS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 > 50% reduction in pain 2 64 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.37, 1.39]
Comparison 4. High pulse amplitude TENS versus low pulse amplitude TENS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain intensity (100 mm VAS) 2 172 Mean Difference (IV, Random, 95% CI) -23.47 [-29.60, -17.
34]
71Transcutaneous electrical nerve stimulation for acute pain (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.1. Comparison 1 TENS versus placebo TENS, Outcome 1 Pain intensity (100 mm VAS).
Review: Transcutaneous electrical nerve stimulation for acute pain
Comparison: 1 TENS versus placebo TENS
Outcome: 1 Pain intensity (100 mm VAS)
Study or subgroup TENS Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Cheing 2005 (1) 10 17 (17) 9 46 (20) 10.2 % -29.00 [ -45.79, -12.21 ]
Ordog 1987 (2) 25 30.4 (26) 25 54.8 (25) 12.1 % -24.40 [ -38.54, -10.26 ]
Amer-Cuenca 2011 (3) 30 24.6 (24.6) 30 57.3 (27.9) 12.8 % -32.70 [ -46.01, -19.39 ]
Amer-Cuenca 2011 (4) 30 26.5 (24.7) 30 61.9 (23.2) 13.9 % -35.40 [ -47.53, -23.27 ]
Hruby 2006 (5) 48 35 (28.8) 49 43.7 (30.6) 14.1 % -8.70 [ -20.52, 3.12 ]
Oncel 2002 (6) 25 24 (13) 25 39 (20) 16.5 % -15.00 [ -24.35, -5.65 ]
Kim 2012 (7) 50 19 (12) 50 48 (15) 20.4 % -29.00 [ -34.32, -23.68 ]
Total (95% CI) 218 218 100.0 % -24.62 [ -31.79, -17.46 ]
Heterogeneity: Tau2 = 58.21; Chi2 = 18.13, df = 6 (P = 0.01); I2 =67%
Test for overall effect: Z = 6.73 (P < 0.00001)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
Favours TENS Favours Placebo
(1) Outcome measured on day 11 after 10 days of TENS treatment. TENS not on during measurement
(2) Outcome measured after day 2 of treatment. NRS (0-10) used presented as mean+SD. TENS not on during measurement
(3) Outcome measured 5 minutes into procedure (mean duration procedure 17-20 min depending on group). TENS on during measurement
(4) Outcome measured at end of procedure (mean duration 17-20 min depending on group). TENS on during measurement
(5) Outcome measured after 1 minute of TENS. TENS on during measurement
(6) NOTE: Comparison with placebo pill. Outcome measured on day 4 receiving TENS for 3 days. TENS not on during measurement.
(7) Outcome measured after 20 minutes of TENS. TENS not on during measurement
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Analysis 1.2. Comparison 1 TENS versus placebo TENS, Outcome 2 > 50% reduction in pain.
Review: Transcutaneous electrical nerve stimulation for acute pain
Comparison: 1 TENS versus placebo TENS
Outcome: 2 > 50% reduction in pain
Study or subgroup TENS Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ekblom 1987 (1) 3/11 1/10 6.1 % 2.73 [ 0.34, 22.16 ]
Ekblom 1987 (2) 4/11 1/10 6.1 % 3.64 [ 0.48, 27.33 ]
Hansson 1983 (3) 9/20 2/20 11.6 % 4.50 [ 1.11, 18.27 ]
Hansson 1983 (4) 7/22 2/20 12.1 % 3.18 [ 0.75, 13.57 ]
Amer-Cuenca 2011 (5) 17/30 3/30 17.3 % 5.67 [ 1.85, 17.34 ]
Roche 1985 (6) 21/28 2/8 18.0 % 3.00 [ 0.89, 10.15 ]
Amer-Cuenca 2011 (7) 19/30 5/30 28.9 % 3.80 [ 1.63, 8.85 ]
Total (95% CI) 152 128 100.0 % 3.91 [ 2.42, 6.32 ]
Total events: 80 (TENS), 16 (Placebo)
Heterogeneity: Chi2 = 0.84, df = 6 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 5.58 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Placebo Favours TENS
(1) 2Hz TENS with muscle contractions (AL-TENS)
(2) 100z sensory TENS (conventional TENS)
(3) 100z sensory TENS (conventional TENS)
(4) 2Hz TENS with muscle contractions (AL-TENS)
(5) Outcome measured at end of procedure (mean duration 17-20 min depending on group). TENS on during measurement
(6) Outcome measured immediatey after 25 minutes of TENS. TENS not on during measurement
(7) Outcome measured 5 minutes into procedure (mean duration procedure 17-20 min depending on group). TENS on during measurement
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Analysis 2.1. Comparison 2 TENS versus no treatment control, Outcome 1 Pain intensity (100 mm VAS).
Review: Transcutaneous electrical nerve stimulation for acute pain
Comparison: 2 TENS versus no treatment control
Outcome: 1 Pain intensity (100 mm VAS)
Study or subgroup TENS
No
Treatment
Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
de Sousa 2014 (1) 16 35.6 (17.8) 16 48.1 (23.7) 12.7 % -12.50 [ -27.02, 2.02 ]
Amer-Cuenca 2011 (2) 30 24.6 (24.6) 30 49.1 (31.6) 12.8 % -24.50 [ -38.83, -10.17 ]
Amer-Cuenca 2011 (3) 30 26.5 (24.7) 30 54.7 (30.1) 13.1 % -28.20 [ -42.13, -14.27 ]
Pitangui 2012 (4) 20 8.9 (21.5) 20 39.4 (19.8) 13.9 % -30.50 [ -43.31, -17.69 ]
Hruby 2006 (5) 48 35 (28.8) 51 34.4 (30.5) 14.7 % 0.60 [ -11.08, 12.28 ]
Pitangui 2012 (6) 20 13.6 (15.3) 20 41 (21.8) 14.7 % -27.40 [ -39.07, -15.73 ]
De Angelis 2003 (7) 71 37.1 (20.6) 71 50.7 (20.3) 18.3 % -13.60 [ -20.33, -6.87 ]
Total (95% CI) 235 238 100.0 % -19.05 [ -27.30, -10.79 ]
Heterogeneity: Tau2 = 85.32; Chi2 = 20.87, df = 6 (P = 0.002); I2 =71%
Test for overall effect: Z = 4.52 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours TENS Favours No Treatment
(1) Time point used = 2nd assessment/feed. Measurement taken using NRS at rest (converted to 100 unit scale). Data presented as Mean+SD
(2) Outcome measured 5 minutes into procedure (mean duration procedure 17-20 min depending on group). TENS on during measurement
(3) Outcome measured at end of procedure (mean duration 17-20 min depending on group). TENS on during measurement
(4) Outcome measured 60 after start of TENS . TENS on during measurement. Measurement taken using NRS at rest. Data presented as Mean+SD
(5) Outcome measured after 1 minute of TENS. TENS on during measurement
(6) Outcome measured 120 minutes after start of TENS . TENS on during measurement. Measurement taken using NRS at rest. Data presented as Mean+SD
(7) Outcome measured after procedure. TENS not on during measurement
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Analysis 3.1. Comparison 3 Conventional TENS versus AL-TENS, Outcome 1 > 50% reduction in pain.
Review: Transcutaneous electrical nerve stimulation for acute pain
Comparison: 3 Conventional TENS versus AL-TENS
Outcome: 1 > 50% reduction in pain
Study or subgroup Conventional TENS AL-TENS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ekblom 1987 3/11 4/11 29.8 % 0.75 [ 0.22, 2.60 ]
Hansson 1983 7/22 9/20 70.2 % 0.71 [ 0.32, 1.54 ]
Total (95% CI) 33 31 100.0 % 0.72 [ 0.37, 1.39 ]
Total events: 10 (Conventional TENS), 13 (AL-TENS)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours AL-TENS Favours Conventional TENS
Analysis 4.1. Comparison 4 High pulse amplitude TENS versus low pulse amplitude TENS, Outcome 1 Pain
intensity (100 mm VAS).
Review: Transcutaneous electrical nerve stimulation for acute pain
Comparison: 4 High pulse amplitude TENS versus low pulse amplitude TENS
Outcome: 1 Pain intensity (100 mm VAS)
Study or subgroup High PA TENS Low PA TENS
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Liu 1985 (1) 15 46 (19.5) 15 61.3 (30.6) 11.1 % -15.30 [ -33.66, 3.06 ]
De Angelis 2003 (2) 71 37.1 (20.6) 71 61.6 (18.9) 88.9 % -24.50 [ -31.00, -18.00 ]
Total (95% CI) 86 86 100.0 % -23.47 [ -29.60, -17.34 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.86, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 7.51 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours High PA TENS Favours Low PA TENS
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(1) Outcome measured on day 1 post-surgery. TENS not on during measurement. Participants dropped out as study progressed if pain had resolved
(2) Outcome measured after procedure. TENS not on during measurement
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Table 1. Studies excluded as TENS given in combination with other treatments (Continued)
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Please note we may have had other reasons for exclusion of above studies in addition to the fact that TENS was used in combination
with other treatments.
A P P E N D I C E S
Appendix 1. Ovid MEDLINE search strategy
1. exp Pain/
2. Pain Measurement/
3. Pain Threshold/
4. Pain Clinics/
5. Myofascial Pain Syndromes/
6. Hyperalgesia/
7. exp Headache Disorders/
8. (toothache$ or tooth-ache$ or ear-ache$ or earache$ or sciatic$ or neuralgi$ or migraine$ or headache$ or neuralgi$ or cephalalgi$
or metatarsalgia$ or bursitis or hyperalg$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer name]
9. pain$.ti.
10. pain$.ab.
11. exp Angina Pectoris/
12. angina.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manu-
facturer name]
13. Metatarsalgia/
14. or/1-13
15. exp Transcutaneous Electric Nerve Stimulation/
16. “TENS”.ti.
17. “TENS”.ab.
18. “TNS”.ti.
19. “TNS”.ab.
20. “ENS”.ti.
21. “ENS”.ab.
22. (“transcutaneous electric$ nerve stimulation” or “transcutaneous nerve stimulation”).mp. [mp=title, abstract, subject headings,
heading word, drug trade name, original title, device manufacturer, drug manufacturer name]
23. (“electric$ nerve stimulation” or “electrostimulation therap$” or “electro-stimulation therap$”).mp. [mp=title, abstract, subject
headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]
24. (“electric$ nerve therap$” or electroanalgesi$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer name]
25. transcutaneous electric$ stimulation.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device
manufacturer, drug manufacturer name]
26. TES.ti,ab.
27. or/15-26
28. 14 and 27
29. RANDOMIZED CONTROLLED TRIAL.pt.
30. CONTROLLED CLINICAL TRIAL.pt.
31. RANDOMIZED CONTROLLED TRIALS.sh.
32. RANDOM ALLOCATION.sh.
33. DOUBLE BLIND METHOD.sh.
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34. SINGLE BLIND METHOD.sh.
35. or/29-34
36. (ANIMALS not HUMAN).sh.
37. 35 not 36
38. CLINICAL TRIAL.pt.
39. exp CLINICAL TRIALS/
40. (clin$ adj25 trial$).ti,ab.
41. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.
42. PLACEBOS.sh.
43. placebo$.ti,ab.
44. random$.ti,ab.
45. RESEARCH DESIGN.sh.
46. or/38-45
47. 46 not 36
48. 47 not 37
49. 37 or 48
50. 28 and 49
Appendix 2. PaPaS Specialized Register search strategy
((pain* or hyperalgesi* or headache* or migrain* or toothache or “tooth ache*” or earache or “ear ache*” or sciatic* or neuralgi* or
cephalgi* ormetatarsalg* or bursitis or angina) AND(“transcutaneous electric* nerve stimulation” or “transcutaneous nerve stimulation”
or “electric* nerve stimulation” or “electrostimulation therap*” or electroanalgesi* or TENS))
Appendix 3. CENTRAL (the Cochrane Library) search strategy
1. MeSH descriptor Pain explode all trees in MeSH products
2. MeSH descriptor Pain Measurement, this term only in MeSH products
3. MeSH descriptor Pain Threshold, this term only in MeSH products
4. MeSH descriptor Pain Clinics, this term only in MeSH products
5. MeSH descriptor Myofascial Pain Syndromes, this term only in MeSH products
6. MeSH descriptor Hyperalgesia, this term only in MeSH products
7. MeSH descriptor Headache Disorders explode all trees in MeSH products
8. (Toothache* or tooth-ache* or ear-ache* or earache* or sciatic* or neuralgi* or migrain* or headache* or neuralgi* or cephalalgia
or metatarsalgia* or bursitis or hyperalg*) in All Fields in all products
9. pain* in Record Title in all products
10. pain* in Abstract in all products
11. MeSH descriptor Angina Pectoris explode all trees in MeSH products
12. angina in All Fields in all products
13. MeSH descriptor Metatarsalgia, this term only in MeSH products
14. (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13)
15. MeSH descriptor Transcutaneous Electric Nerve Stimulation explode all trees in MeSH products
16. “TENS” in Record Title in all products
17. “TENS” in Abstract in all products
18. “TNS” in Record Title in all products
19. “TNS” in Abstract in all products
20. “ENS” in Record Title in all products
21. “ENS” in Abstract in all products
22. (transcutaneous next electric* next nerve next stimulation or “transcutaneous nerve stimulation” ) in All Fields in all products
23. (“electric* nerve stimulation” or “electrostimulation therap*” ) in All Fields in all products
24. (“electric* nerve therap*” or electroanalgesi*) in All Fields in all products
25. “TES” in Record Title in all products
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26. “TES” in Abstract in all products
27. (transcutaneous next electric* next stimulation) in All Fields in all products
28. (#15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27)
29. (#14 AND #28)
Appendix 4. Ovid EMBASE search strategy
1. exp PAIN/
2. Pain Assessment/
3. Pain Threshold/
4. Pain Clinic/
5. Myofascial Pain/
6. HYPERALGESIA/
7. exp “Headache and Facial Pain”/
8. (toothache$ or tooth-ache$ or ear-ache$ or earache$ or sciatic$ or neuralgi$ or migraine$ or headache$ or neuralgi$ or cephalalgi$
or metatarsalgia$ or bursitis or hyperalg$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer name]
9. pain$.ti.
10. pain$.ab.
11. exp Angina Pectoris/
12. angina.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manu-
facturer name]
13. METATARSALGIA/
14. or/1-13
15. exp Transcutaneous Nerve Stimulation/
16. “TENS”.ti.
17. “TENS”.ab.
18. “TNS”.ti.
19. “TNS”.ab.
20. “ENS”.ti.
21. “ENS”.ab.
22. (“transcutaneous electric$ nerve stimulation” or “transcutaneous nerve stimulation”).mp. [mp=title, abstract, subject headings,
heading word, drug trade name, original title, device manufacturer, drug manufacturer name]
23. (“electric$ nerve stimulation” or “electrostimulation therap$” or “electro-stimulation therap$”).mp. [mp=title, abstract, subject
headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]
24. (“electric$ nerve therap$” or electroanalgesi$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer name]
25. transcutaneous electric$ stimulation.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device
manufacturer, drug manufacturer name]
26. TES.ti,ab.
27. or/15-26
28. 14 and 27
29. random$.ti,ab.
30. factorial$.ti,ab.
31. (crossover$ or cross over$ or cross-over$).ti,ab.
32. placebo$.ti,ab.
33. (doubl$ adj blind$).ti,ab.
34. (singl$ adj blind$).ti,ab.
35. assign$.ti,ab.
36. allocat$.ti,ab.
37. volunteer$.ti,ab.
38. CROSSOVER PROCEDURE.sh.
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39. DOUBLE-BLIND PROCEDURE.sh.
40. RANDOMIZED CONTROLLED TRIAL.sh.
41. SINGLE BLIND PROCEDURE.sh.
42. or/29-41
43. ANIMAL/ or NONHUMAN/ or ANIMAL EXPERIMENT/
44. HUMAN/
45. 44 and 43
46. 43 not 45
47. 42 not 46
48. 28 and 47
Appendix 5. EBSCO CINAHL search strategy
1 exp PAIN/
2 PAIN MEASUREMENT/
3 PAIN CLINICS/
4 MYOFASCIAL PAIN SYNDROMES/
5 HYPERALGESIA/
6 exp HEADACHE/
7 (toothache* OR tooth-ache* OR ear-ache* OR earache* OR sciatic* OR neuralgi* ORmigraine* OR headache* OR neuralgi* OR
cephalalgi* OR metatarsalgia* OR bursitis OR hyperalg*).ti,ab
8 pain*.ti,ab
9 exp ANGINA PECTORIS/
10 angina.ti,ab
11 PAIN THRESHOLD/
12 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11
13 exp TRANSCUTANEOUS ELECTRIC NERVE STIMULATION/
14 (TENS OR TNS OR ENS).ti,ab
15 (transcutaneous AND stimulation).ti,ab
16 TES.ti,ab
17 ((electric* AND stimulation) OR electrostimulation OR electro-stimulation).ti,ab
18 ((electric* nerve therap*) OR electroanalgesi*).ti,ab
19 13 OR 14 OR 15 OR 16 OR 17 OR 18
20 12 AND 19
21 RANDOM ASSIGNMENT/
22 SINGLE-BLIND STUDIES/
23 DOUBLE-BLIND STUDIES/
24 TRIPLE-BLIND STUDIES/
25 CROSSOVER DESIGN/
26 FACTORIAL DESIGN/
27 ((multicentre OR multicenter OR multi-centre OR multi-center) AND stud*).ti,ab
28 random*.ti,ab
29 (latin AND square).ti,ab
30 (cross-over OR crossover).ti,ab
31 PLACEBOS/
32 placebo*.ti,ab
33 ((singl* OR doubl* OR trebl* OR tripl*) AND (blind* OR mask*)).ti,ab
34 exp CLINICAL TRIALS/
35 (clin* AND trial*).ti,ab
36 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33 OR 34 OR 35
37 20 AND 36
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Appendix 6. Ovid AMED search strategy
1. exp Pain/
2. Pain measurement/
3. Pain threshold/
4. PAIN CLINICS.mp.
5. Myofascial pain syndromes/
6. Hyperalgesia/
7. exp Headache/
8. (toothache$ or tooth-ache$ or ear-ache$ or earache$ or sciatic$ or neuralgi$ or migraine$ or headache$ or neuralgi$ or cephalalgi$
or metatarsalgia$ or bursitis or hyperalg$).mp. [mp=title, subject heading word, abstract, instrumentation]
9. pain$.ti.
10. pain$.ab.
11. exp angina pectoris/
12. angina.mp. [mp=title, subject heading word, abstract, instrumentation]
13. Metatarsalgia/
14. or/1-13
15. exp Transcutaneous electric nerve stimulation/
16. “TENS”.ti.
17. “TENS”.ab.
18. “TNS”.ti.
19. “TNS”.ab.
20. “ENS”.ti.
21. “ENS”.ab.
22. (“transcutaneous electric$ nerve stimulation” or “transcutaneous nerve stimulation”).mp. [mp=title, subject heading word, abstract,
instrumentation]
23. (“electric$ nerve stimulation” or “electrostimulation therap$” or “electro-stimulation therap$”).mp. [mp=title, subject heading
word, abstract, instrumentation]
24. (“electric$ nerve therap$” or electroanalgesi$).mp. [mp=title, subject heading word, abstract, instrumentation]
25. transcutaneous electric$ stimulation.mp. [mp=title, subject heading word, abstract, instrumentation]
26. TES.ti,ab.
27. or/15-26
28. 14 and 27
29. RANDOMIZED CONTROLLED TRIAL.pt.
30. CONTROLLED CLINICAL TRIAL.pt.
31. RANDOMIZED CONTROLLED TRIALS.sh.
32. RANDOM ALLOCATION.sh.
33. DOUBLE BLIND METHOD.sh.
34. “single blind method”.mp. [mp=title, subject heading word, abstract, instrumentation]
35. or/29-34
36. (ANIMALS not HUMANS).sh.
37. 35 not 36
38. CLINICAL TRIAL.pt.
39. exp CLINICAL TRIALS/
40. (clin$ adj25 trial$).ti,ab.
41. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.
42. PLACEBOS.sh.
43. placebo$.ti,ab.
44. random$.ti,ab.
45. RESEARCH DESIGN.sh.
46. or/38-45
47. 46 not 36
48. 47 not 37
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49. 37 or 48
50. 28 and 49
Appendix 7. PEDro search strategy
Abstract & Title:“electrical stimulation” pain
Therapy: electrotherapies, heat and cold
Problem: pain
Method: Clinical Trial
Note: check “match all search terms”
Appendix 8. OTseeker search strategy
Keywords: electrical stimulation
Methods: clinical trial
Appendix 9. OpenSIGLE search strategy
((pain OR toothache* OR tooth-ache* OR ear-ache* OR earache* OR sciatic* OR neuralgi* OR migraine* OR headache* OR
neuralgi* OR cephalalgi* OR metatarsalgia* OR bursitis OR hyperalg* OR myofascial OR angina*) AND (transcutaneous electric
nerve stimulation OR tens OR tns OR ens OR transcutaneous electric* OR transcutaneous nerve stimulation OR electric* nerve
stimulation OR electrostimulation therap* OR electro-stimulation therap* OR electro-stimulation OR electrostimulation OR electric*
nerve therap* OR electroanalgesi*))
Appendix 10. Search strategies for 2014 update
CENTRAL (the Cochrane Library)
#1 MeSH descriptor: [Pain] explode all trees
#2 MeSH descriptor: [Pain Measurement] this term only
#3 MeSH descriptor: [Pain Threshold] this term only
#4 MeSH descriptor: [Pain Clinics] this term only
#5 MeSH descriptor: [Myofascial Pain Syndromes] this term only
#6 MeSH descriptor: [Hyperalgesia] this term only
#7 MeSH descriptor: [Headache Disorders] explode all trees
#8 (toothache* or tooth-ache* or ear-ache* or earache* or sciatic* or neuralgi* or migraine* or headache* or neuralgi* or cephalalgi* or
metatarsalgia* or bursitis or hyperalg*):ti,ab,kw (Word variations have been searched)
#9 pain*:ab or pain*:ti (Word variations have been searched)
#10 MeSH descriptor: [Angina Pectoris] explode all trees
#11 angina:ti,ab,kw (Word variations have been searched)
#12 MeSH descriptor: [Metatarsalgia] this term only
#13 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12
#14 MeSH descriptor: [Transcutaneous Electric Nerve Stimulation] explode all trees
#15 (“TENS” or “TNS” or “ENS” or “TES”):ti,ab,kw (Word variations have been searched)
#16 (“transcutaneous electric* nerve stimulation” or “transcutaneous nerve stimulation”):ti,ab,kw (Word variations have been searched)
#17 (“electric* nerve stimulation” or “electrostimulation therap*” or “electro-stimulation therap*”):ti,ab,kw (Word variations have been
searched)
#18 (“electric* nerve therap*” or electroanalgesi*):ti,ab,kw (Word variations have been searched)
#19 “transcutaneous electric* stimulation”:ti,ab,kw (Word variations have been searched)
#20 #14 or #15 or #16 or #17 or #18 or #19
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#21 #13 and #20 from 2011 to 2014
MEDLINE (OVID) & Medline In-Process (OVID)
1. exp Pain/
2. Pain Measurement/
3. Pain Threshold/
4. Pain Clinics/
5. Myofascial Pain Syndromes/
6. Hyperalgesia/
7. exp Headache Disorders/
8. (toothache$ or tooth-ache$ or ear-ache$ or earache$ or sciatic$ or neuralgi$ or migraine$ or headache$ or neuralgi$ or cephalalgi$ or
metatarsalgia$ or bursitis or hyperalg$).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword
heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
9. pain$.ti.
10. pain$.ab.
11. exp Angina Pectoris/
12. angina.mp.
13. Metatarsalgia/
14. or/1-13
15. exp Transcutaneous Electric Nerve Stimulation/
16. (“TENS” or “TNS” or “ENS”).ti.
17. (“TENS” or “TNS” or “ENS”).ab.
18. (“transcutaneous electric$ nerve stimulation” or “transcutaneous nerve stimulation”).mp.
19. (“electric$ nerve stimulation” or “electrostimulation therap$” or “electro-stimulation therap$”).mp.
20. (“electric$ nerve therap$” or electroanalgesi$).mp.
21. transcutaneous electric$ stimulation.mp.
22. TES.ti,ab.
23. or/15-22
24. 14 and 23
25. randomized controlled trial.pt.
26. controlled clinical trial.pt.
27. randomized.ab.
28. placebo.ab.
29. drug therapy.fs.
30. randomly.ab.
31. trial.ab.
32. or/25-31
33. exp animals/ not humans.sh.
34. 32 not 33
35. 24 and 34
36. (2011* or 2012* or 2013* or 2014*).ed.
37. 35 and 36
EMBASE (OVID)
1. exp Pain/
2. Pain Measurement/
3. Pain Threshold/
4. Pain Clinics/
5. Myofascial Pain Syndromes/
6. Hyperalgesia/
7. exp Headache Disorders/
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8. (toothache$ or tooth-ache$ or ear-ache$ or earache$ or sciatic$ or neuralgi$ or migraine$ or headache$ or neuralgi$ or cephalalgi$
or metatarsalgia$ or bursitis or hyperalg$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
9. pain$.ti.
10. pain$.ab.
11. exp Angina Pectoris/
12. angina.mp.
13. Metatarsalgia/
14. or/1-13
15. exp Transcutaneous Electric Nerve Stimulation/
16. (“TENS” or “TNS” or “ENS”).ti.
17. (“TENS” or “TNS” or “ENS”).ab.
18. (“transcutaneous electric$ nerve stimulation” or “transcutaneous nerve stimulation”).mp.
19. (“electric$ nerve stimulation” or “electrostimulation therap$” or “electro-stimulation therap$”).mp.
20. (“electric$ nerve therap$” or electroanalgesi$).mp.
21. transcutaneous electric$ stimulation.mp.
22. TES.ti,ab.
23. or/15-22
24. 14 and 23
25. random$.tw.
26. factorial$.tw.
27. crossover$.tw.
28. cross over$.tw.
29. cross-over$.tw.
30. placebo$.tw.
31. (doubl$ adj blind$).tw.
32. (singl$ adj blind$).tw.
33. assign$.tw.
34. allocat$.tw.
35. volunteer$.tw.
36. Crossover Procedure/
37. double-blind procedure.tw.
38. Randomized Controlled Trial/
39. Single Blind Procedure/
40. or/25-39
41. (animal/ or nonhuman/) not human/
42. 40 not 41
43. 24 and 42
AMED (OVID)
1. exp Pain/
2. Pain Measurement/
3. Pain Threshold/
4. Pain Clinics/
5. Myofascial Pain Syndromes/
6. Hyperalgesia/
7. (toothache$ or tooth-ache$ or ear-ache$ or earache$ or sciatic$ or neuralgi$ or migraine$ or headache$ or neuralgi$ or cephalalgi$
or metatarsalgia$ or bursitis or hyperalg$).mp. [mp=abstract, heading words, title]
8. pain$.ti.
9. pain$.ab.
10. exp Angina Pectoris/
11. angina.mp.
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12. Metatarsalgia/
13. (or/1-6) or 7 or 8 or 9 or 10 or 11 or 12
14. exp Transcutaneous Electric Nerve Stimulation/
15. (“TENS” or “TNS” or “ENS”).ti.
16. (“TENS” or “TNS” or “ENS”).ab.
17. (“transcutaneous electric$ nerve stimulation” or “transcutaneous nerve stimulation”).mp.
18. (“electric$ nerve stimulation” or “electrostimulation therap$” or “electro-stimulation therap$”).mp.
19. (“electric$ nerve therap$” or electroanalgesi$).mp.
20. transcutaneous electric$ stimulation.mp.
21. TES.ti,ab.
22. or/14-21
23. 13 and 22
CINAHL (EBSCO)
S32 S30 AND S31
S31 EM 20110101-20141231
S30 S20 AND S29
S29 S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28
S28 (allocat* random*)
S27 (MH “Quantitative Studies”)
S26 (MH “Placebos”)
S25 placebo*
S24 (random* allocat*)
S23 (MH “Random Assignment”)
S22 (Randomi?ed control* trial*) Limiters - Published Date: 20090101-20130231
S21 (singl* blind* ) or (doubl* blind* ) or (tripl* blind* ) or (trebl* blind* ) or (trebl* mask* ) or (tripl* mask* ) or (doubl* mask* ) or
(singl* mask* )
S20 S12 AND S19
S19 S13 OR S14 OR S15 OR S16 OR S17 OR S18
S18 “transcutaneous electric* stimulation”
S17 (“electric* nerve therap*” or electroanalgesi*)
S16 (“electric* nerve stimulation” or “electrostimulation therap*” or “electro-stimulation therap*”)
S15 (“transcutaneous electric* nerve stimulation” or “transcutaneous nerve stimulation”)
S14 (“TENS” or “TNS” or “ENS” or “TES”)
S13 (MH “Transcutaneous Electric Nerve Stimulation”)
S12 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11
S11 (MH “Metatarsalgia”)
S10 angina
S9 (MH “Angina Pectoris+”)
S8 TI pain* OR AB pain*
S7 (toothache* or tooth-ache* or ear-ache* or earache* or sciatic* or neuralgi* or migraine* or headache* or neuralgi* or cephalalgi* or
metatarsalgia* or bursitis or hyperalg*)
S6 (MH “Hyperalgesia”)
S5 (MH “Myofascial Pain Syndromes”)
S4 (MH “Pain Clinics”)
S3 (MH “Pain Threshold”)
S2 (MH “Pain Measurement”)
S1 (MH “Pain+”)
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WH A T ’ S N E W
Last assessed as up-to-date: 3 December 2014.
Date Event Description
12 June 2015 Review declared as stable At 2015, the authors and editors agreed to reassess this review for further updating in
2020
H I S T O R Y
Protocol first published: Issue 3, 2006
Review first published: Issue 2, 2009
Date Event Description
20 November 2014 New search has been performed We updated the review using a search conducted up
to 3 December 2014
17 January 2014 New citation required but conclusions have not
changed
We included seven new trials in this update. In total,
there were 19 includedRCTswith 1346 participants at
entry, and 11 trials awaiting classification. The analysis
provides tentative evidence that TENS reduces pain
intensity over and above that seen with placebo (no
current) TENS when administered as a stand-alone
treatment for acute pain in adults. However, there is
high risk of bias associated with inadequate sample
sizes in treatment arms and unsuccessful blinding of
treatment interventions. Thismakes definitive conclu-
sions impossible
7 January 2011 New search has been performed Updated search done in January 2011. No new in-
cluded studies but two new studies are awaiting clas-
sification (Gregorini 2010; Rajpurohit 2010) and an
additional 12 studies were assessed and excluded from
this review (Akhmadeeva 2010; Andersen 2009a; An-
dersen 2009b; Barbarisi 2010; Dogu 2009; Durmus
2009; Gul 2009; Korkmaz 2010; Murina 2008; Strat-
ton 2009; Tsai 2010; Wang 2009). A further 17 stud-
ies were excluded as TENS was given with another
treatment (see Table 1)
1 May 2008 Amended Protocol converted to new review format
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the 2011 update we decided to use the Cochrane Collaboration’s ’Risk of bias’ assessment tool to ascertain the methodological
quality of trials (instead of Jadad’s scale) as this is now the Cochrane Collaboration’s recommended tool for all Cochrane Reviews. We
excluded trials if TENS was given in combination with any other treatment, either pharmacological or non-pharmacological. We have
listed the trials we excluded for this reason in Table 1.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Acute Pain [etiology; ∗therapy]; PainMeasurement; Randomized Controlled Trials as Topic; Transcutaneous Electric Nerve Stimulation
[∗methods]
MeSH check words
Adult; Humans
95Transcutaneous electrical nerve stimulation for acute pain (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
